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Natural products continue to be a fertile source of leads for drug discovery, as a 
large extent of the world’s biodiversity has been untapped for their chemical diversity 
and biological activity. With the continuing need for new drug leads due to the increasing 
emergence of drug-resistant pathogens and diseases, this dissertation focused on three 
key strategies in drug discovery including: use of structure-activity relationship studies 
starting with a known bioactive pharmacophore; exploration of understudied ecological 
groups for new chemistry; and development of dereplication strategies. 
Fungal secondary metabolites are known to possess privileged pharmacophores 
that can be ideal starting points for semi-synthetic (or synthetic) approaches to explore 
structure-activity relationship and produce new therap utic candidates. In this work we 
examined the effect of fluorine substitution as a str tegy to expand the therapeutically-
relevant chemical space of isolated fungal secondary metabolites. The chemical space of 
the isolated and synthesized fungal secondary metabolites were characterized by principal 
component analysis to correlate the observed bioactivities.    
Undoubtedly, fungi have an excellent track record in providing chemical entities 
that can be developed into life-saving therapeutics. Freshwater ascomycetes, an 
ecologically distinct group of fungi, offer a unique opportunity to discover new chemical 
diversity, as they are underexplored in comparison to other niches. Chemical 
investigations of freshwater fungal isolates presented in this dissertation led to the 
isolation and identification of new secondary metabolites. These studies highlighted the 
untapped potential of this group of organisms. 
One of the major challenges of working with natural products is the re-isolation of 
known compounds. Thus, to circumvent this issue and increase the efficiency of the 
discovery of new leads, a dereplication methodology using a complementary suite of 
hyphenated techniques, specifically ultra-performance liquid chromatography-photodiode 
array-high resolution tandem mass spectrometry for targeted screening of compounds 
was developed. In conjunction to this, the identified hits were expanded upon by 
screening for potential analogues using mass defect filt ring.  
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CHAPTER I 
INTRODUCTION 
 
 
Nature’s molecular archive has long been a reliable source of structural and 
functional inspiration in the development of therapeutic drugs to treat human diseases.1-3 
It is the single most valuable source of drugs, as over half of the small-molecule approved 
drugs presently constitute of natural products or have a structure derived from, or a 
mimic of, a  natural product.1 Natural products has made significant impacts, particularly 
in the areas of cancer therapies and antibiotics.4-6 However, in the past decades a majority 
of pharmaceutical companies has deemphasized relianc  on drug discovery efforts in 
natural products in favor of synthetic combinatorial high-throughput screening methods. 
The main reason frequently cited for this shift is the decrease in the productivity in terms 
of the discovery of novel structures in natural products.6  
This shift, unfortunately, has not met the expected surge in productivity in terms 
of new leads to fill the demand in the drug discovery pipeline. Rather, it led to a decline 
in the number of new approved chemical entities as drugs.7 This may be of little surprise, 
as Nature has always been an important source for lad compounds suitable for drug 
development. The dominance of natural product derivatives that are developed as drugs 
owes largely to their immense chemical structural diversity and biological relevance.8 
The potency of natural products may be explained in an evolutionary point of view,
2 
 
wherein these secondary metabolites were produced as biologically active chemicals 
providing adaptive value to the producing organism.9 Bioactive natural product scaffolds 
have been well recognized as privileged structures, as they provide ideal starting points 
for drug discovery. Biologically relevant natural products are also known for their 
structural complexity, and thus, optimization of their structure to improve inherent drug-
like properties is often difficult.  Structural diversification is usually accomplished by 
semi-synthetic approaches to explore structure-activity relationships and produce new 
drug candidates.  
With the continuing need for novel structures as antibiotics and 
chemotherapeutics, natural products remain relevant to the future of drug discovery. 
Addressing the demand for unique structural diversity, this dissertation has focused on: 
use of structure-activity relationship studies starting with a known bioactive 
pharmacophore from filamentous fungi (Chapter II); exploration of understudied 
ecological groups for new chemistry with emphasis on freshwater ascomycetes (Chapters 
III and IV); and implementation of dereplication strategies (Chapter V). 
Fungi are non-photosynthetic microorganisms that ply an important ecological 
role as agents of biodegradation and biodeterioration.10 Fungi have been known to have a 
high biodiversity, second to insects, that is six times greater than the recognized species 
of terrestial plants.10-12 According to current estimates, about 1.5 million12 of fungal 
species exists on Earth but only about 135,00013 of these have been described 
taxonomically. From these described species, only a fraction have been studied for their 
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chemistry.14 To date, there are only about 25,000 fungal secondary metabolites reported, 
and only for a third of these, the bioactivity have been assigned.14 Therefore, fungi 
represent a nearly limitless source for new natural products that can be used as 
therapeutics leads for drug development.  
Fungi are known to biosynthesize a wide array of secondary metabolites with 
various biological activities. A few species of fungi produce mycotoxins, compounds that 
are known to be toxic, which can cause a variety of negative effects on plants, animals, 
and humans.15 On the other hand, fungi also produce numerous important 
pharmaceuticals that have tremendous impact on human he lth (Figure 1).  
Historically, natural products from fungi have been one of the most successful 
sources of drugs that have had broad therapeutic use.  The discovery of penicillin from 
Penicillium notatum  by Alexander Fleming in 1929,3,16 which saved millions of lives, 
paved the way for the discovery of more antibiotics17 from other fungal sources. 
Cyclosporin is a natural cyclic polypeptide antifungal-antibiotic isolated from 
Tolypocladium inflatum.18  Its discovery was important as it is medicinally useful in 
suppressing immune responses when transplants are graft d.19  Another significant class 
of fungal-derived drugs are the statins, also known as hydroxymethylglutaryl-CoA 
(HMG-CoA) reductase inhibitors, used to lower blood cholesterol levels.  Currently, at 
least three statins are in clinical use including lovastatin and mevastatin, fungal secondary 
metabolites mainly produced by Aspergillus terreus and Monascus ruber, and P. 
citrinum, respectively, and simvastatin a semi-synthetic derivative of lovastatin.20-22 
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Another remarkable fungal-derived natural product is gr seofulvin. Griseofulvin 
was first isolated and identified from P. griseofulvum in 1939.24 It was developed and 
approved as an antifungal drug against superficial skin infections in both humans and 
animals in 1959.25 Recently, griseofulvin is being considered for cancer treatment due to 
its antimitotic and antiproliferative activities against various types of cancer cells.26-29 
Recent studies suggest that griseofulvin in combinatio  with nocodazole, an 
antineoplastic agent, hinders tumor production in both in vitro and in vivo assays by 
induction of apoptosis and G2/M cell cycle arrest.26 Additionally, griseofulvin has been 
found to inhibit centrosomal clustering, making tumor cells with supernumerary 
 
Figure 1. Fungal-Derived Drugs That Have Had a Great Impact on Public Health.  
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centrosomes to undergo multipolar mitoses, thereby l ading to cell apoptosis.27,30  
Griseofulvin has a mode of action that is still not well understood, but disruption of the 
microtubule assembly by tubulin binding in both fungal and mammalian cells has been 
proposed.25,28,31  
Chapter II centers on the isolation and characterization of griseofulvin and six 
related analogues (one new to literature) from a culture of Xylaria cubensis (accessioned 
as MSX48662). The isolation of these fungal metabolites presented an opportunity to 
evaluate the anticancer and antifungal potential of these compounds. Additionally, this 
allowed us to investigate the influence of semi-synthetic strategies-fluorination 
specifically, in expanding the medicinally-relevant chemical space of the isolated fungal 
metabolites.  
One of the important steps in the discovery of new bioactive natural products is 
the careful selection of the source to investigate. A majority of earlier drug discovery 
studies performed on fungi involve organisms collected from terrestrial habitats. 
However, as rediscovery of previously identified metabolites has become increasingly 
frequent, other habitats have been explored to expand chemical diversity beyond the 
terrestrial microorganisms. Several approaches havebeen used in the search for new 
chemistry with potential bioactivity, and one of these includes an ecology-based 
rationale.32-34 It is hypothesized that fungi thrive in competitive or unique ecosystems 
because they have evolved to produce secondary metabolites that provide them with 
selective advantage over other competing organisms.35,36 It is therefore predicted that 
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fungi from different habitats would produce a diverse and unique collection of secondary 
metabolites different from their terrestrial counterparts. 
Freshwater ascomycetes are an ecological group that is relatively unexplored in 
terms of its mycology and chemistry. These species belong to the phylum Ascomycota, 
which is the largest and most phylogenetically diverse group of organisms in the 
Kingdom Fungi.37 Freshwater ascomycetes are a taxonomically different group 
comprising of species of fungi that have part or their whole life cycle in freshwater 
environments, including lentic (lakes, ponds, and swamps) and lotic habitats (rivers, 
streams, creeks, and brooks).38-41 These fungi mostly occur on submerged woody and 
herbaceous debris, serving as organic matter decomposers.42  
Studies on freshwater ascomycetes have only been initiated recently, and these 
organisms still remain poorly known.  To date, there a e about 675 described species 
from freshwater habitats.43 This reported number has increased from a meager 300 
species described worldwide from an initial comprehensive review by Shearer.39 Despite 
the recent efforts for intensive fungal collections i  the past two decades, knowledge on 
the chemistry of freshwater ascomycetes is still lagging. 
To help bridge this knowledge gap, our group is focused on the investigation of 
fungi collected systematically from different freshwater sources across North Carolina, 
USA. North Carolina has a unique geographical locati n, where it is divided into four 
distinct areas including ranges of the Appalachian Mountains in the western part of the 
state, Piedmont plateau, Atlantic coastal plain, and the outer banks in the east. With this 
variety in the geographical features of North Carolina, we hypothesize that the freshwater 
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ascomycetes from this area have high fungal species div rsity. Additionally, these 
freshwater ascomycetes may have unique adaptations for survival prompting the need for 
the production of chemically diverse compounds thatcould potentially be used as new 
therapeutic leads. 
Chapters III and IV are devoted to the isolation and characterization of secondary 
metabolites from organic extracts of two freshwater scomycetes (accessioned as G416 
and G730) collected from two different regions in North Carolina. Investigation of G416 
(recently identified as Lindgomyces madisonensis Raja & Oberlies) collected from a 
submerged wood from Big Beaver Island creek in Madison, North Carolina, led to the 
isolation of seven acetophenone derivatives (five new to literature and two newly 
reported as natural products; Chapter III). These fungal secondary metabolites were 
evaluated for their antimicrobial activity against a panel of pathogenic bacteria and fungi. 
Chapter IV presents the isolation and identification of three new prenylated xanthenes as 
well as two known compounds from an organic extract of G730. The fungal strain G730 
was isolated from submerged wood collected from a freshwater lake in Hanging Rock 
State Park, North Carolina. Phylogenetic analysis on a fungal isolate of G730, tentatively 
identified as Leotiomycetes sp., indicated that the strain may represent a new genus 
and/or species. Chapter IV also details the characterization of the antivirulence potential 
of the three new prenylated xanthenes against methicillin resistant Staphylococcus 
aureus. 
One of the key driving forces for natural products drug discovery efforts is the 
identification of new chemical structures that can be used as new drug leads. Therefore, 
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quick recognition of previously known compounds, refe red to as dereplication, in fungal 
fermentation extracts play a prominent role in drug discovery screening programs. 
Efficient implementation of dereplication strategies aims to reduce timelines for the “hit-
to-lead” process, as well as maximize available financial resources.   
An efficient dereplication procedure involves analytical methods that are reliable, 
robust, rapid, and sensitive to be able to characterize natural products as pure compounds, 
and even more so in complex mixtures.44  Chapter V demonstrates the use of an 
ultraperformance liquid chromatography-photodiode array-high resolution tandem mass 
spectrometry (UPLC-PDA-HRMS-MS/MS)-based dereplication system to perform 
targeted screening of secondary metabolites produced by fungi. The application of this 
UPLC-PDA-HRMS-MS/MS dereplication method has facilitated rapid confirmation of 
known fungal secondary metabolites at the level of crude extracts. Moreover, in Chapter 
V, mass defect filtering, a post-acquisition data an lysis technique, is presented as an 
additional approach for the targeted screening of secondary metabolites in fungal 
extracts.  The merger of UPLC-PDA-HRMS-MS/MS dereplication with mass defect 
filtering permits additional profiling for structurally related components in the sample 
based on their mass defects. Mass defect filtering therefore allowed characterization for a 
wider range of secondary metabolites produced by fungal cultures.  
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CHAPTER II 
CHEMOSELECTIVE FLUORINATION AND CHEMOINFORMATIC ANALYSIS OF  
GRISEOFULVIN: NATURAL VS FLUORINATED FUNGAL METABOLITE 
 
 
This chapter is intended for publication to Bioorganic and Medicinal Chemistry 
(2017) and is presented in that style. Coauthors include Mohammed Al-Huniti, 
Huzefa A. Raja, Austin Czarnecki, Joanna E. Burdette, Mariana González-
Medina, José L. Medina-Franco, Stephen J. Polyak, Cedric J. Pearce, Mitchell P. 
Croatt, Nicholas H. Oberlies. 
 
 
 Griseofulvin is a fungal metabolite and antifungal drug used for the treatment of 
dermatophytosis in both humans and animals. Recently, griseofulvin and its analogues 
have attracted renewed attention due to reports of their potential anticancer effects. In this 
study griseofulvin (1) and related analogues (2-6, with 4 being new to literature) were 
isolated from Xylaria cubensis and screened for activity against a panel of cancer cell 
lines (MDA-MB-435, MDA-MB-231, OVCAR3, and Huh7.5.1) and for antifungal 
activity against Microsporum gypseum. In addition, six fluorinated analogues (7-12) were 
synthesized to examine the effects of fluorine incorporation on the bioactivities of this 
structural class. A comparison of the chemical space occupied by the natural and 
fluorinated analogues was carried out by using principal component analysis, 
documenting that the isolated and fluorinated analogues occupy complementary regions 
of chemical space. However, the most active compounds, i cluding two fluorinated 
derivatives, were centered around the chemical space that was occupied by the parent 
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compound, griseofulvin, suggesting that modifications must preserve certain attributes of 
this privileged pharmacophore to conserve its activity. 
Introduction 
Bioactive secondary metabolites have had a long history in medicine, as they 
provide privileged scaffolds for drug discovery.45-48 As testament to this, from 1981 to 
2014 over half of the new small molecule drugs approved by the U.S. FDA were natural 
products or natural product-derived/natural product-inspired.1,49 The success of natural 
products as source of therapeutic agents is driven by their biochemical specificity and 
high chemical diversity, occupying distinct regions of chemical space that coincide with 
clinically relevant areas.46,50  
Fungi are one of the most species-rich organisms, second only to insects, offering 
a vast resource for discovery of new drug leads. Our recent collaborative efforts 
underscore the structural complexity and diversity of fungal metabolites.50-52 As 
promising compounds are identified, these structural features are of particular relevance, 
as they can be used to stimulate semi-synthetic53,54 approaches to explore structure-
activity relationships and produce new drug candidates. 
The natural product griseofulvin (1, Figure 2), (2S,6'R)-7-chloro-2',4,6-
trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione, is a potent 
antifungal drug orally administered for the treatment of dermatophytosis (i.e., fungal 
infection of the skin) in both humans and animals.55-58 Since its isolation and discovery 
from a filamentous fungus in 1939,24 most research has focused on the identification of 
griseofulvin analogues, either from nature or synthetically, but to date, only the original 
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compound (1) has been developed into a marketable antifungal drug, first approved in 
1959.56  Recently, there has been a renewed interest in 1 due to its antimitotic and 
antiproliferative activities against various types of cancer cells.26,27,29,30,59 Griseofulvin 
has a mode of action that is still not well understood, but disruption of the microtubule 
dynamics in both fungal and mammalian cells has been proposed.25,56,60 Thus, aside from 
being an antifungal drug, it may also be a clinically-viable candidate for cancer 
chemotherapy.25,31,59-62 Due to these reasons, it was decided that griseofulvin was worth 
further investigation.  
The introduction of fluorine into a bioactive compound has been shown to impart 
a range of effects, often altering physicochemical profiles by modulating acid/base 
properties, electronegativity, lipophilicity, and metabolic stability.63,64 Focusing on these 
unique properties, fluorine has been exploited in the design and optimization of 
biologically active molecules.63,65,66 With our interest in late stage fluorination of 
secondary metabolites,53 we envisioned the ability to prepare various fluorinated 
griseofulvin derivatives. We further rationalized tha  1, already proven to be a successful 
therapeutic, was a good candidate to investigate the influence of flu rine substitution as a 
strategy to expand the medicinally-relevant chemical sp ce of fungal metabolites. 
An isolate of the filamentous fungus Xylaria cubensis (strain MSX48662) was 
found to be a prolific producer of 1, biosynthesizing over 100 mg per a single rice-based 
fermentation culture grown in a 2.8 L Fernbach flask,67 and thus, it was used for resupply 
purposes. Hence, the fungal extract was subjected to further studies and afforded six 
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compounds, including 1 and structurally related analogues, four of which were known (2, 
3, 5, and 6) and one of which (4) was new to the literature. Seven additional analogues (7, 
8a/8b, 9-12, all fluorinated) were produced using 1, 3 and 4 as starting materials. All 12 
compounds were evaluated for cytotoxicity against cancer cell lines, including human 
melanoma cancer cells (MDA-MB-435), human breast cancer cells (MDA-MB-231), 
human ovarian cancer cells (OVCAR3), and human hepatom  (Huh7.5.1) cells68. 
Moreover, the antifungal potency of 1-12 against Microsporum gypseum was assessed in 
a disk diffusion assay. Characterization of the chemical space of the isolated and 
synthesized analogues was also carried out by princi al omponent analysis to correlate 
structural modifications with the observed bioactivities. 
Results and Discussion 
Isolation of griseofulvin (1) and related analogues (2-6). Organic extracts 
(CHCl3/CH3OH) from the rice-based fermentation cultures of MSX48662 were 
partitioned with organic solvents, subjected to flash chromatography, and were purified 
using preparative HPLC to yield griseofulvin (1) and five structurally related analogues 
(2-6), with 4 being new to literature. The structures of compounds 1-3 and 5-6 were 
established by analysis of HRESIMS and NMR data, all of which compared favorably to 
the literature (See the Supporting Information for spectral data).69,70 
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 R1  R2 R3 
1 Cl  H CH3 
2 Cl  OH CH3 
3 H  H CH3 
4 H  OH CH3 
5 H  H H 
6 Cl  H H 
 
Figure 2. Structures of Griseofulvin (1) and Related Analogues (2-6) Isolated from 
Xylaria cubensis. 
 
 
Compound 4 was isolated as a white solid. The NMR and HRESIMS data (m/z 
335.1119 [M+H]+) both indicated a molecular formula of C17H18O7, corresponding to a 
difference of an additional OH (16 Da) relative to 3. The 1H NMR spectrum of 4 (Table 7 
and Figures 9-11) showed similarities to 3, including signals for a 1,2,3,5-tetrasubstituted 
aromatic ring, as evidenced by the meta-coupled arom tic proton signals at δH 6.06 and 
δH 6.22  (3JHH = 1.1 Hz), an isolated olefinic proton, three methoxy groups, as well as a 
methyl group. However, it was also clear from these data that the diastereotopic 
methylene proton α-H-5´ in 3 was replaced with a hydroxy moiety in 4, thus shifting β-H-
5´ to the more downfield region of the spectrum (δH 4.71). The large coupling constant 
(3JHH = 12.1 Hz) observed between H-5´ and H-6´ placed both protons in trans-diaxial 
positions, imparting 5´-OH and 6´-CH3 in equatorial positions, analogous to that of 2. 
Based on these observations, the configuration at C-5´ was established as R. A 
comparison of the observed specific rotation value ([α]D27 +343) of 4 with those for 1 
([α]D27 +340), 2 ([α]D27+306) and 3 ([α]D27 +386) revealed that the configurations at C-2 
(S) and C-6´ (R) of these compounds were identical. Thus, the structu e of compound 4
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was established as shown (Figure 2) and identified as (2S,5 Ŕ,6 Ŕ)- 7-dechloro-5´-
hydroxygriseofulvin.   
Semi-synthesis and structure elucidation of fluorinated analogues. There are a 
few reports on the fluorination of griseofulvin and its analogues.71,72 For example, 
monofluorinated and difluorinated griseofulvin analogues have been prepared by Taub 
and co-workers in 1963 and Barton and co-workers in 1972 by electrophilic fluorination 
of griseofulvin using either perchloryl fluoride (FClO3)73,74 or fluoroxytrifluoromethane 
(CF3OF),75 two of the earliest electrophilic fluorine reagents. These harsh conditions 
resulted in the formation of several mono- and difluorinated products, including reaction 
of the enol-ether and some g m-difluoro derivatives. In this study, our goal was to 
chemoselectively fluorinate ring A of griseofulvin without affecting the other functional 
groups, especially the enol-ether motif. Thus, Selectfluor, was used as the electrophilic 
fluorination reagent, since it is known to be milder and typically more chemoselective 
than other fluorination reagents.76-78 Indeed, this strategy yielded only ring A fluorinated-
derivatives; each substrate gave two mono-fluorinated compounds, with fluorination at 
either C-5 or C-7, which allowed us to probe the chmical space of these analogues.  
  
15 
 
       
 
       
  
  
         
 
Figure 3. Semi-Synthesis of Fluorinated Compounds 7-12 with Selectfluor. The 
percent yields shown were calculated based on recovered starting material. 
 
 
Seven fluorinated products (7, 8a/8b, 9-12) were obtained from Selectfluor 
reactions with compounds 1, 3, and 4 (Figure 3). Addition of a solution of 1 (dissolved in 
CH3CN) to a CH3CN solution of Selectfluor afforded one minor compound (7) and an 
inseparable diastereoisomeric mixture of 8a/8b with a ratio of 2:1, as revealed by 
interpretation of the 1H NMR data (Figure 19).  The HRMS data for 7 indicated the 
incorporation of one fluorine atom with a molecular formula of C17H16ClFO6. A 
comparison of the 1H NMR data (Table 10, Figure 14) of 7 with 1 suggested the 
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attachment of a fluorine atom into ring A, as evidenced by the absence of the aromatic H-
5 signal. In addition, the methoxy groups at C-4 and C-6 resonated as doublets due to 
through-space coupling79 with a coupling constant of JHF = 3.1 Hz for both. Their 
chemical shifts were slightly downfield (∆δ 0.14-0.22, Figure 15) due to their proximity 
to the F atom at C-5. 19F-13C HMQC data (Figure 16) showed a correlation between th  
fluorine atom and C-5, which resonated as a doublet at δC 142.9 with a large coupling 
constant of 244.3 Hz typical of a 1JCF bond in an aromatic ring,80 further supporting the 
position of fluorine. Additionally, the doublet signals observed for C-4 (2JCF = 9.0 Hz) 
and C-6 (2JCF = 12.1 Hz) corroborate the attachment of fluorine at C-5.  Altogether, these 
data identify 7 as 5-fluorogriseofulvin, which was previously reported by Barton and co-
workers by the treatment of griseofulvin with fluoroxytrifluoromethane.72 
The NMR and HRESIMS data (m/z 357.0543 [M+H]+) for compounds 8a/8b 
supported a molecular formula of C16H14ClFO6. Following the interpretation of edited-
HSQC (Figure 20) and HMBC (Figure 21) experiments, the 13C and 1H NMR data (Table 
11) were assignable to 16 carbon atoms consisting of two methoxy groups, one methyl, 
three methine (two sp2 and one sp3), one methylene, and nine non-protonated carbons 
(three carbonyls, four olefinic with three of them oxygenated, and two fully substituted 
carbons). Comparison of the NMR data between 1 a d 8a/8b indicated that rings B and C 
of both compounds were identical. However, modifications were made in ring A of 
8a/8b, as the NMR data indicated oxidation at C-4 to a ketone due to the absence of a 
methoxy group and the presence of an extra carbonyl carbon (δC 176.9).  The doublet 
signal observed for H-5 (3JHF = 1.8 Hz) and the doublet signal observed for 19F (3JHF = 
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1.8 Hz) indicated the addition of fluorine to ring A (Figure 22). The doublet signal (1JCF 
~243 Hz) observed for C-7, along with an HMQC correlation between 19F and C-7 (δC 
~94), suggested the attachment of fluorine to C-7 (Figure 23). The assignment of fluorine 
being at C-7 was further supported by the doublet splitting patterns observed for C-6 
(2JCF = 19.1 Hz) and C-7a (2JCF = 21.0 Hz). Thus, the structures of the diastereoisomers 
were assigned as shown in Figure 3. We have previously bserved similar reactivity with 
Selectfluor reactions,53 as have others with Selectfluor81 and other related reagents82-88. 
 The reaction of Selectfluor with 3 afforded two mono-fluorinated structural 
isomers 9 (major) and 10 (minor), both with a molecular formula of C17H17FO6 based on 
HRESIMS data. Comparison of the 1H NMR data of 9 (Table 12) and 10 (Table 13) with 
those of 3 indicated the loss of one aromatic proton signal attributed to H-5 and H-7, 
respectively. In compound 9, the C-4 methoxy resonance appeared more deshielded 
compared with the corresponding signal in 3 (∆δ 0.3), and showed a doublet splitting 
pattern due to a through space coupling with the fluorine at C-5 (Figure 24-25). Unlike its 
chloro-analogue (7), this coupling was observed for the methoxy group at C-4 only, 
which suggested that, in the preferred conformer, the methoxy group at C6 in 9 is rotated 
away from the fluorine. Alternatively, compound 7 prefers to adopt a conformation where 
the methoxy group at C-6 is in close proximity to the fluorine due to the steric effect 
imposed by the chlorine atom.89,90 On the other hand, the methoxy groups in compound 
10 showed no through-space coupling with the fluorine. 
 1H NMR data for compound 9 also showed a doublet at δ 6.37 (3JHF = 6.3 Hz), 
which was assigned to H-7 due to long-range coupling with fluorine (Figure 24-25). The 
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correlation detected between the fluorine and C-5 (δC 139.6, doublet, 1JCF = 237.5 Hz) in 
the 19F-13C-HMQC data (Figure 26) suggested the connection of flu rine to position 5. 
The attachment of fluorine at C-5 was further corroborated by the small doublet splitting 
observed for C-4 (2JCF = 8.8 Hz) and C-6 (2JCF = 11.3 Hz), establishing the structure of 9 
as 5-fluoro-7-dechlorogriseofulvin. The structure of 10 was established in an analogous 
manner and was identified as 7-fluoro-7-dechlorogriseofulvin (Table 13; Figure 29-33), 
which was previously reported by Taub and co-workers.71 
As was the case for 3, reaction of compound 4 with Selectfluor yielded two 
mono-fluorinated structural isomers, 11 and 12. The HRESIMS data served to verify the 
number of incorporated fluorine atoms in the compounds, while the NMR data was 
analyzed in the same manner as 9 (Table 14-15; Figure 34-43). This exercise established 
the structures of 11 and 12 as the 5′-OH analogues of compounds 9 and 10, respectively.  
Biological evaluation. Griseofulvin (1) and all 11 analogues (2-12) were 
evaluated for their cytotoxic activity against three different cancer cell lines, specifically 
MDA-MB-435, MDA-MB-231, and OVCAR3 (Table 1 and Table 16).  
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Table 1. Cytotoxicity Results for the Active Compounds.a  
 
Compound 
IC50 
MDA-MB-435c MDA-MB-231d OVCAR3e 
1 6.4 µM inactive 48.5 µM 
10 22.0 µM inactive inactive 
Vinblastineb 0.5 nM 8.8 nM 1.8 nM 
aA compound was indicated as inactive if no activity was 
observed at 50 µM. Compounds 2-9 and 11-12 were inactive 
(see Table 16). 
bPositive control; cHuman melanoma cancer cells; dHuman 
breast cancer cells 
eHuman ovarian cancer cells 
 
 
Compounds 1 and 10 had moderate cytotoxicity, with IC50 values ranging from 
approximately 6 to 50 µM. As a complementary dataset, w  also tested 1-12 for 
cytotoxicity in human hepatoma Huh7.5.1 cells; the data were in agreement (refer to 
Figure 44 and Table 18). These results were in accordance with earlier studies,25,91 
demonstrating that structural modifications in the 2´ position retain or increase the 
cytotoxicity of the analogues, while alterations at any other position do not retain the 
cytotoxicity of 1, as was the case for all the analogues tested in this study.  
All compounds (1-12) were also tested in an antifungal assay against 
Microsporum gypseum, a dermatophyte that causes tinea capitis, tinea corpus, and other 
fungal infections of the skin.92,93   As shown in Tables 2 and 17, compound 10 retained 
the activity of 1, while 7 showed a slight decrease in activity. Compound 10 has 
previously been reported to retain the activity of 1 against the plant pathogen Botrytis 
alii,71 but its activity against dermatophytes, particularly M. gypseum, has not been 
reported. The antifungal activity of 7 has not been reported previously.  
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Table 2. Antifungal Results Against Microsporum gypseum 
for the Active Compounds.a  
 
Compound 
Zone of Inhibition 
(mm)a 
25 µg/disk 
1b 35 ± 1 
7 23 ± 1 
10 34 ± 1 
aMean diameter of inhibition zones expressed as the mean of 
four replicates ± standard deviation. Results for the Other 
Compounds in this Study are Shown in Table S15. 
bPositive control 
 
 
Principal component analysis. The introduction of fluorine into molecules often 
results in significant changes in their molecular properties and biological activities.66,94 
The small atomic size, very high electronegativity, and low polarizability of the fluorine 
atom are just a few of the characteristics that can have important consequences in a lead 
optimization program, particularly one focused on modifying privileged scaffolds. To 
compare the distribution in chemical space between th  natural analogues (1-6) versus the 
fluorinated analogues (7-12), principal component analysis (PCA) was performed. Eleven 
molecular properties that describe the electron distribution, molecular surface, and 
solubility of the compounds were used in an attempt to emphasize the variation given by 
the addition of a fluorine, with the goal of finding a pattern in the data set. The first two 
principal components (PC1, PC2) retrieved 68% of the covariance, whereas the first three 
principal components (PC1 – PC3) retrieved 87% of the covariance. Interestingly, two 
electronic descriptors, namely electron affinity (EA (eV)) and electrotopological state 
(Estate), had the highest contribution to PC1, while QPlogS, a descriptor related to the 
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solubility of the compounds, had the highest contribution to PC2. The dipole moment of 
the molecule, an electronic descriptor, had the highest contribution to PC3. These results 
further emphasized that the addition of a fluorine atom changed mostly the electronic 
distribution within the molecules, as reflected in the clear separation in the PCA of the 
fluorinated vs. non-fluorinated analogues of griseofulvin (Figure 4). 
 
 
 
Figure 4. Visual Representation of the Chemical Space of Griseofulvin (1, Red), 
Structurally Related Fungal Analogues (2-6, Green) and Fluorinated 
Semisynthetic Derivatives (7-12, Blue). This 3D plot was generated with the 
principal component analysis of 11 descriptors. Thefirst three principal components 
recovered 87% of the covariance. The electron affinity (EA (eV)) and 
electrotopological state (Estate) had the highest con ribution to the first principal 
component, while the predicted aqueous solubility (QPlogS) had the highest 
contribution to the second principal component. Lastly, dipole moment had the 
highest contribution to the third principal component. 
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The 3D representation of the chemical space of 1-12 revealed several interesting 
features (Figure 4). For example, the 3D plot showed that the fungal metabolites 
clustered together, occupying a distinct region in the chemical space different from the 
fluorinated analogues, further illustrating that fluorine incorporation modified the 
molecular properties of the analogues. Additionally, f uorinated analogues 7, 9, and 10 
were closer to griseofulvin in chemical space, suggesting that these analogues had similar 
electron distribution, solubility, and surface characteristics, which could indicate that 
these compounds had similar bioactivities. Similar results were observed on the 2D plot 
with PC1 and PC2 (Figure 45). The correlation betwen similarity in chemical space and 
similarity in bioassay results held true for 7 and 10 but not for 9. For 7, this observation 
can be rationalized given that the van der Waals radius of a fluorine atom (1.47 Å) is only 
slightly larger than that of hydrogen (1.20 Å). For c mpound 7, the replacement of the 
hydrogen atom with a fluorine atom at C-5 did not impart a large change in molecular 
volume or the overall structure of the compound, thus retaining the antifungal activity. 
The highly electronegative nature and the geometric size of chlorine at C-7 of ring A is 
an important feature of 1 in order to retain its biological effect. The properties of the 
chlorine atom, particularly at the C-7 position (orth  relative to the C-6 methoxy group), 
may also impart steric constraints and/or electrostatic effects that may be necessary for 
optimum molecular recognition between the compound a  an active site/receptor. 
Compound 9 lacks the chlorine atom at the C-7 position, and this may explain why no 
biological activity was observed for this compound. A fluorine atom at C-7, instead of 
chlorine, as was the case in compound 10, may induce a similar electronic effect on the 
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compound. The difference in electronegativity between the fluorine and carbon creates a 
large dipole moment in this bond, contributing to the overall electronic nature of the 
molecule, and this could lead to specific interactions with an active site/receptor. 
Although 10 retains the antifungal activity and cytotoxicity of 1, a decrease in potency 
was observed, which may be explained by a decrease in th steric bulk in 10 at C-7 due to 
a difference in van der Waals radius between a fluorine atom (1.47 Å) and chlorine (1.75 
Å). The differences in activity observed for 7 and 10 against M. gypseum and the cancer 
cell lines could indicate a difference in the mode f action of 1 toward fungal and 
mammalian cells, which is still a subject of some debate.25,56,95  
A 2D plot of predicted aqueous solubility (QPlogS) and electron affinity (eV) 
similarly illustrated the variance in the distribution of the analogues across the chemical 
space (Figure 5). The addition of an electrophilic fluorine to the griseofulvin analogues 
increased the electron affinity of the compounds, and this was manifested in chemical 
space as separating the fluorinated analogues from the natural secondary metabolites. 
Compound 7, which is the C-5 fluorinated derivative of 1, shared similar molecular 
properties in chemical space as 1, but compared to the natural fungal analogues, 7 had a 
higher electron affinity. Moreover, Figures 4 and 5 illustrate that analogues 8a/8b, which 
lost the aromaticity at ring A, were in a different region of chemical space, far from the 
rest of the analogues. Overall, it was observed that in 8a/8b the addition of a fluorine to 
ring A significantly altered the properties of these compounds compared to griseofulvin 
(1). These changes could explain in part why 8a/8b were inactive. Overall, the addition 
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of fluorine or a hydroxy group to the A or C rings improved the predicted solubility 
(Figure 5). 
  
 
 
Figure 5. A 2D Visual Representation of the Chemical Space of Griseofulvin (1, 
Red), Structurally Related Fungal Analogues (2-6, Green) and Fluorinated 
Semisynthetic Derivatives (7-12, Blue ). The 2D representation was generated using 
two descriptors, predicted aqueous solubility (QPlogS; y-axis) and electron affinity 
[EA(Ev); x-axis]. The substructures found on the derivatives and natural products but 
not on griseofulvin’s structure are depicted in red. 
 
 
Conclusion 
In summary, griseofulvin (1) and five analogues (2-6), with 4 being new to the 
literature, were isolated from X. cubensis. Additionally, a series of fluorinated analogues 
(7-12) were synthesized, each requiring only a single step from the isolated natural 
products using Selectfluor. The chemoselective nature of Selectfluor allowed for direct, 
site-specific mutation of the natural products without the use of protecting groups or 
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other redox-modifications. Of the synthesized analogues, 8a/8b, 9, 11, 12 are reported for 
the first time. All compounds were tested against the dermatophyte M. gypseum and in 
cytotoxicity assays against human melanoma cancer cells (MDA-MB-435), human breast 
cancer cells (MDA-MB-231), human ovarian cancer cells (OVCAR3), and human 
hepatoma cells (Huh7.5.1). Of the analogues, 10 retained the activity of 1 against M. 
gypseum, while 7 displayed less potency. Only compound 10 exhibited cytotoxic activity, 
but was less active compared to 1 against the MDA-MB-231 cells. To visualize the 
differences in the molecular and physicochemical prope ties generated by the addition of 
a single fluorine atom to the fungal secondary metabolites, PCA was used based on 
descriptors related to the electron distribution, solubility and molecular surface of the 
compounds. These descriptors captured the variation in the molecular properties and 
demonstrated that fluorinated analogues occupy a different region of chemical space than 
the fungal secondary metabolites. In addition, it was observed that the compounds 7 and 
10 were close to griseofulvin in the chemical space, results that were consistent with the 
bioassay testing. Taken together, these results demonstrate the value of cheminformatics 
analyses to study structure-properties relationships and anticipate if a compound could be 
active based on similarity to a known active compound. 
Experimental Section 
 General experimental procedures. All solvents and chemicals were purchased 
from standard suppliers and were used without any further purification. The NMR data 
were collected using either a JEOL ECS-400 spectrometer (JEOL USA, Inc.) operating at 
400 MHz for 1H and 100 MHz for 13C, and equipped with JEOL normal geometry 
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broadband Royal probe; or a JEOL ECA-500 spectrometer (JEOL USA, Inc.) operating 
at 500 MHz for 1H and 125 MHz for 13C; or an Agilent 700 MHz NMR spectrometer 
(Agilent Technologies, Inc., Santa Clara, CA, USA) operating at 700 MHz for 1H and 
175 MHz for 13C, and equipped with a cryoprobe. NMR chemical shift values were 
referenced to residual solvent signals for CDCl3 (δH/δC 7.26/77.2). Data for 1H NMR are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, sept = septet, m = multiplet), coupling constant (Hz), and 
integration; whereas 13C NMR analyses were reported in terms of chemical shift. 
HRESIMS data were obtained using a Thermo QExactive Plus mass spectrometer 
(ThermoFisher, San Jose, CA, USA) with an electrospray ionization source coupled with 
a Waters Acquity ultraperformance liquid chromatography (UPLC) system (Waters 
Corp.). The UPLC separation was performed using an Acquity BEH C18 column (50 mm 
x 2.1 mm i.d., 1.7 µm) equilibrated at 40 °C and a flow rate set at 0.3 mL/min. The 
mobile phase consisted of a linear CH3 N/H2O (acidified with 0.1% HCOOH) gradient 
starting at 15% CH3CN to 100% CH3CN over 8 min. The mobile phase was held for 
another 1.5 min at 100% CH3CN before going back to the starting conditions. The HPLC 
separations were performed using Varian ProStar HPLC system connected to a ProStar 
335 photodiode array detector (PDA) with UV detection set at 210 nm and 254 nm. 
Preparative reversed phase HPLC purification of samples was performed on a 
Phenomenex Gemini-NX C18 (5 µm; 250 × 21.2 mm) column using a 21 mL/min flow 
rate of the mobile phase consisting of a mixture of CH3CN and H2O (with 0.1% 
HCOOH). Flash column chromatography was carried out with a Teledyne ISCO 
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Combiflash Rf connected to an ELSD and PDA detectors with UV detection set at 200-
400 nm. Optical rotation data were acquired on a Rudolph Research Autopol III 
polarimeter (Rudolph Research Analytical, Flanders, NJ, USA). The UV data were 
acquired using a Varian Cary 100 Bio UV‒ is spectrophotometer (Varian Inc., Walnut 
Creek, CA, USA). The optical density (OD) at 600 nmwas acquired using Thermo 
ScientificTM GenesysTM 20. 
 Fungal strain identification. Fungal strain MSX48662 was isolated from cedar 
wood collected in Little Rock, Arkansas and was identified using morphological and 
molecular methods96 as described in detail previously.67 Based on morphological 
characterization and molecular phylogenetic analysis, strain MSX48662 was identified as 
Xylaria cubensis (Sordariomycetes, Ascomycota). The sequence data for he strain 
utilized in the study was deposited in GenBank under accession number KX229783.   
Fermentation, extraction, and isolation of natural products (1-6). The 
fermentation of fungal strain MSX48662 was performed using procedures described 
previously with slight modifications. 97-99 Briefly, a fresh culture of the fungus was grown 
on a malt extract slant. Subsequently, a small agarplug with mycelium was inoculated in 
a liquid medium consisting of 2% soy peptone, 2% dextrose, and 1% yeast extract 
(YESD media). This was followed by incubation for approximately 7 days at room 
temperature (22 ̊C) with shaking. The seed culture was used to inoculate a Fernbach flask 
(2.8 L) containing rice (150 g) and H2O (300 mL) and grown at rt for a period of 20 days.  
The solid fermentation culture was extracted by addition of 1:1 CH3OH/CHCl3 
(500 mL), followed by agitation for 16 h, and filtered. To the filtrate, 900 mL of CHCl3 
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and 1500 mL of H2O were added, and stirred for 30 min. The biphasic solution was 
partitioned, and the organic phase was collected and dried in vacuo. The resulting dried 
extract was further partitioned between CH3O /CH3CN (1:1, 300 mL) and hexanes (300 
mL) to obtain fractions weighing 2 g and 4 g, respectiv ly. The CH3OH/CH3CN soluble 
partition was then adsorbed on Celite 545, and subjected to silica flash chromatography 
on a 24 g RediSep Rf Gold Si-gel column, eluting with use of a gradient solvent system 
of hexane/CHCl3/CH3OH at a flow rate of 35 mL/min over 71 column volumes for a 
duration of 68 min to give 100 fractions each containing 25 mL. The resulting fractions 
were then pooled according to their ELSD and UV profiles, which resulted to 16 
subfractions.  
 Fraction 6 (230 mg) was subjected to preparative re rsed-phase HPLC eluting 
with a linear gradient from 30% to 50% CH3CN in H2O (0.1% HCOOH) over 30 min to 
afford compound 1 (92 mg, tR  = 20.0 min), 2 (1.0 mg, tR = 15.5 min), 3 (64 mg, tR  = 16.5 
min), and 4 (15 mg, 12.5 min).  Fraction 7 (115 mg) was purified using the same 
preparative HPLC conditions yielding more of compounds 2 (11 mg, tR  = 15.5 min) and 
4 (17 mg, tR  = 12.5 min).  Fraction 9 (250 mg) was similarly chromatographed but using 
a linear gradient from 20% to 40% CH3CN in H2O (0.1% HCOOH) over 15 min followed 
by an increase in the gradient to 80% CH3 N to afford compounds 5 (1.9 mg, tR  =  17.0 
min) and 6 (2.7 mg, tR  = 21.5 min). 
Griseofulvin ((2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione; 1): White solid; [α]D27 +340 (c 0.1, CHCl3); UV 
(MeOH) λmax (log ε) 236 (4.4), 291 (4.4), 331 (3.7) nm; 1H NMR (400 MHz, CDCl3) δ = 
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0.96 (d, J = 6.8 Hz, 3H), 2.42 (dd, J = 16.8 Hz, 4.6 Hz, 1H), 2.84 (m, 1H), 3.03 (dd, J =
16.8 Hz, 13.4 Hz, 1H), 3.61 (s, 3H), 3.98 (s, 3H), 4.03 (s, 3H), 5.53 (s, 1H), 6.13 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ = 14.4, 36.5, 40.1, 56.5, 56.8, 57.1, 89.5, 90.9, 97.3, 
105.0, 105.2, 157.9, 164.7, 169.6, 170.9, 192.6, 197.2 (See Table 4 and Figure 6); 
HRESIMS m/z 353.0781 [M+H]+ (calc’d for C17H18ClO6, 353.0786). 
5'-Hydroxygriseofulvin ((2S,5'R,6'R)-7-chloro-5'-hydroxy-2',4,6-trimethoxy-6'-
methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 2): White solid; [α]D27 
+306 (c 0.05, MeOH); UV (MeOH) λmax (log ε) 236 (4.2), 291 (4.2), 331 (3.6) nm; 1H
NMR (700 MHz, CDCl3) δ = 1.11 (d, J = 6.7 Hz, 3H), 2.64 (dq, J = 12.2 Hz, 6.7 Hz, 
1H), 3.65 (s, 3H), 3.99 (s, 3H), 4.04 (s, 3H), 4.68 (d, J = 12.2 Hz, 1H), 5.61 (s, 1H), 6.14 
(s, 1H); 13C NMR (175 MHz, CDCl3) δ = 11.1, 43.6, 56.6, 57.1, 57.2, 71.5, 89.7, 91.2, 
97.4, 101.8, 105.2, 158.0, 165.0, 169.8, 171.5, 192.6, 197.5 (See Table 5 and Figure 7); 
HRESIMS m/z 369.0738 [M+H]+ (calc’d for C17H18ClO7, 369.0736). 
7-Dechlorogriseofulvin ((2S,6'R)-2',4,6-trimethoxy-6'-methyl-3H-
spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 3): White solid; [α]D27 +386 (c 0.1, 
MeOH); UV (MeOH) λmax (log ε) 239 (4.4), 287 (4.4), 321 (3.8) nm; 1H NMR (400 
MHz, CDCl3) δ = 0.94 (d, J = 6.6 Hz, 3H), 2.39 (dd, J = 16.8 Hz, 4.7 Hz, 1H), 2.74 (m, 
1H), 3.03 (dd, J = 16.8 Hz, 13.4 Hz, 1H), 3.61 (s, 3H), 3.89 (s, 3H), 3.90 (s, 3H), 5.53 (s, 
1H), 6.03 (d, J = 1.9 Hz, 1H), 6.23 (d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 
14.4, 36.7, 40.2, 56.2, 56.2, 56.8, 88.6, 90.0, 93.5, 104.4, 104.9, 159.2, 170.5, 171.5, 
176.2, 192.7, 197.6 (Table 6 and Figure 8); HRESIMS m/z 319.1175 [M+H]+ (calc’d for 
C17H19O6, 319.1176). 
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7-Dechloro-5'-hydroxygriseofulvin ((2S,5'R,6'R)-5'-hydroxy-2',4,6-trimethoxy-6'-
methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 4): White solid; [α]D27 
+343 (c 0.1, MeOH); UV (solvent) λmax (log ε) 230 (4.4), 288 (4.4), 321 (3.7) nm; 1H
NMR (400 MHz, CDCl3) δ = 1.11 (d, J = 6.6 Hz, 3H), 2.55 (dq, J = 12.1 Hz, 6.6 Hz, 
1H), 3.66 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 4.71 (d, J = 12.1 Hz, 1H), 5.61 (s, 1H), 6.06 
(d, J = 1.1 Hz, 1H), 6.22 (d, J = 1.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 11.2, 
43.9, 56.3, 56.3, 57.1, 71.5, 88.6, 90.5, 93.7, 101.7, 104.4, 159.3, 170.8, 172.1, 176.3, 
192.6, 197.8. (See Table 9 and Figures 9-11); HRESIMS m/z 335.1119 [M+H]+ (calc’d 
for C17H19O7, 335.1125). 
6-O-desmethyl-7-dechlorogriseofulvin ((2S,6'R)-6-hydroxy-2',4-dimethoxy-6'-
methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 5): White solid; [α]D27 
+221 (c 0.1, MeOH); UV (solvent) λmax (log ε) 248 (4.3), 290 (4.2), 322 (4.2) nm; 1H
NMR (400 MHz, CDCl3) δ = 0.97 (d, 6.7 Hz, 3H), 2.43 (dd, J = 16.7 Hz, 4.8 Hz, 1H), 
2.76 (dqd, J = 13.2 Hz, 6.7 Hz, 4.8 Hz, 1H), 3.08 (dd, J = 16.7 Hz, 13.2 Hz, 1H), 3.64 (s, 
3H), 3.90 (s, 3H), 5.55 (s, 1H), 6.05 (d, J = 1.9 Hz, 1H), 6.20 (d, J = 1.9 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ = 14.4, 36.7, 40.1, 56.3, 56.9, 90.0, 91.7, 93.6, 104.1, 104.7, 
159.9, 167.9, 172.2, 175.8, 192.6, 198.4 (See Table 8 and Figure 12); HRESIMS m/z 
305.1032 [M+H]+ (calc’d for C16H17O6, 305.1020). 
6-O-desmethyl-7-griseofulvin ((2S,6'R)-7-chloro-6-hydroxy-2',4-dimethoxy-6'-
methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 6): White solid; [α]D27 
+278 (c 0.1, MeOH); UV (solvent) λmax (log ε) 243 (4.3), 288 (4.3), 347 (3.7) nm; 1H
NMR (400 MHz, CDCl3) δ = 0.97 (d, J = 6.7 Hz, 3H), 2.44 (dd, J = 16.6 Hz, 4.7 Hz, 
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1H), 2.83 (dqd, J = 13.3 Hz, 6.7 Hz, 4.7 Hz, 1H), 3.04 (dd, J = 16.6 Hz, 13.3 Hz, 1H), 
3.63 (s, 3H), 3.92 (s, 3H), 5.55 (s, 1H), 6.25 (s, 1H); 13C NMR (100 MHz, CDCl3) δ = 
14.4, 36.5, 40.1, 56.6, 56.8, 91.2, 93.6, 95.2, 105.0, 105.4, 158.0, 161.8, 169.9, 170.7, 
192.2, 197.2. (See Table 9 and Figure 13); HRESIMS m/z 339.0646 [M+H]+ (calc’d for 
C16H16ClO6, 339.0630). 
 General fluorination procedure with selectfluor. To an ice-cold acetonitrile 
solution of the natural product was slowly added a freshly prepared acetonitrile solution 
of Selectfluor. The reaction mixture was allowed to stir at 0 °C for 4 h and then heated to 
50 °C and monitored by HPLC. After 24 h, the reaction mixture was cooled to room 
temperature and the solvent was removed in vacuo.  
 Fluorination of griseofulvin (1). Griseofulvin (1) (10.0 mg, 0.028 mmol, 0.02 
M) and Selectfluor (15.1 mg, 0.043 mmol, 0.02 M) were reacted via the general method. 
The residue was purified by preparative HPLC eluting with a linear gradient from 40% to 
60% CH3CN in H2O (0.1% HCOOH) over 30 min to obtain 7 (tR =19 min) and 8a/8b (tR 
=13 min).  
 5-Fluorogriseofulvin ((2S,6'R)-7-chloro-5-fluoro-2',4,6-trimethoxy-6'-methyl-3H-
spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 7):White solid [α]D27 +290 (c 0.1, 
MeOH) 1.0 mg (10 % yield, 21 % yield based on recovred starting material); 1H NMR 
(400 MHz, CDCl3) δ = 0.95 (d, J = 6.7 Hz, 3H), 2.45 (dd, J = 16.7 Hz, 4.4 Hz, 1H), 2.85 
(dqd, J = 13.3 Hz, 6.7 Hz, 4.4 Hz, 1H), 2.98 (dd, J = 16.7 Hz, 13.3 Hz, 1H), 3.64 (s, 3H), 
4.17 (d, J = 3.1 Hz, 3H), 4.20 (d, J = 3.1 Hz, 3H), 5.56 (s, 1H).13C NMR (100 MHz, 
CDCl3) δ = 14.4, 36.6, 40.0, 56.9, 62.1 (d, J = 7.0 Hz), 62.6 (d, J = 6.0 Hz), 90.6, 103.4, 
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105.2, 108.0, 142.9 (d, J = 244.3 Hz), 144.7 (d, J =  9.0 Hz), 153.9 (d, J = 12.1 Hz), 
164.9, 170.5, 193.5 (d, J = 4.0 Hz), 196.8. 19F NMR (470 MHz, CDCl3) δ = -155.5 (sept. 
J = 3.1 Hz) (See Table 10 and Figure 14-18); HRESIMS m/z 371.0696 [M+H]+ (calc’d 
for C17H17ClFO6 371.0692). 
 (2S,6'R)-7-chloro-5-fluoro-2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-
cyclohexan]-2'-ene-3,4'-dione (8a/8b):White solid; 2.3 mg (Isolated as a 
diastereoisomeric mixture of the two compounds with a 2:1 ratio, 23 % yield, 49 % yield 
based on recovered starting material); white solid; 8a:1H NMR (400 MHz, CDCl3) δ = 
1.00 (d, J = 6.3 Hz, 3H), 2.46 (dd, J = 16.1 Hz, 4.2 Hz, 1H), 2.89 (m, 1H), 2.97 (m, 1H), 
3.69 (s, 3H), 3.94 (s, 3H), 5.55 (d, J = 1.8 Hz, 1H), 5.58 (s, 1H ). 13C NMR (100 MHz, 
CDCl3) δ = 14.1, 36.1, 39.7, 57.1, 57.8, 94.1, 94.1 (d, J = 252.3), 102.0 (d, J = 2.0 Hz), 
105.4, 110.1 (d, J = 3.0 Hz), 162.8 (d, J = 19.1 Hz), 168.1, 176.9 (d, J = 2.0 Hz), 185.3 
(d, J = 21.0 Hz), 191.8, 195.8. 19F NMR (470 MHz, CDCl3) δ = -126.4 (d, J = 1.8 Hz). 
8b:1H NMR (400 MHz, CDCl3) δ = 1.06 (d, J = 6.3 Hz, 3H), 2.46 (dd, J = 16.1 Hz, 4.2 
Hz, 1H), 2.95 (m, 1H), 2.97 (m, 1H), 3.67 (s, 3H), 3.94 (s, 3H), 5.55 (d, J = 1.8 Hz, 1H), 
5.58 (s, 1H). 13C NMR (100 MHz, CDCl3) δ = 14.1, 36.5, 39.7, 57.2, 57.8, 94.0 (d, J =
254.3), 94.1, 102.0 (d, J = 2.0 Hz), 105.5, 110.0 (d, J = 3.0 Hz), 162.8 (d, J = 19.1 Hz), 
167.7, 176.9 (d, J = 2.0 Hz), 185.4 (d, J = 21.0 Hz), 191.7, 195.8. 19F NMR (470 MHz, 
CDCl3) δ = -127.5 (d, J = 1.8 Hz) (See Table 11 and Figures 19-23); HRESIMS m/z 
357.0543 [M+H]+ (calc’d for C16H15ClFO6 357.0536). 
 Fluorination of 7-dechlorogriseofulvin (3). 7-Dechlorogriseofulvin (3) (7.0 mg, 
0.022 mmol) and Selectfluor (11.7 mg, 0.033 mmol) were reacted via the general method. 
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The residue was purified by preparative HPLC eluting with a linear gradient from 30% to 
50% CH3CN in H2O (0.1% HCOOH) over 30 min to obtain compounds 9 (tR =21 min), 
and 10 (tR =18 min).  
 5-Fluoro-7-dechlorogriseofulvin ((2S,6'R)-5-fluoro-2',4,6-trimethoxy-6'-methyl-
3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 9):White solid; [α]D27 +289 (c 
0.1, MeOH) 2.3 mg (33 % yield, 46 % yield based on recovered starting material); 1H 
NMR (500 MHz, CDCl3) δ = 0.95 (d, J = 6.9 Hz, 3H), 2.75 (dd, J = 17.2 Hz, 4.6 Hz, 
1H), 2.75 (m, 1H), 3.02 (dd, J = 17.2 Hz, 13.2 Hz, 1H), 3.63 (s, 3H), 3.98 (s, 3H), 4.20 
(d, J = 3.3 Hz, 3H), 5.55 (s, 1H), 6.37 (d, J = 5.2 Hz, 1H). 13C NMR (125 MHz, CDCl3) 
δ = 14.4, 36.7, 40.1, 56.8, 57.0, 62.1 (d, J = 7.5 Hz), 89.8, 90.0, 105.0, 105.5, 139.6 (d, J 
= 237.5 Hz), 145.0 (d, J = 8.8 Hz), 158.6 (d, J = 11.3 Hz), 170.4, 171.1, 193.4, 197.2. 
19F NMR (470 MHz, CDCl3) δ = -163.0 (m) (See Table 12 and Figure 24-28); HRESIMS 
m/z 337.1080 [M+H]+ (calc’d for C17H18FO6 337.1082). 
 7-Fluoro-7-dechlorogriseofulvin ((2S,6'R)-7-fluoro-2',4,6-trimethoxy-6'-methyl-
3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 10):White solid; [α]D27 +230 (c 
0.1, MeOH) 1.3 mg (19 % yield, 26 % yield based on recovered starting material); 1H 
NMR (700 MHz, CDCl3) δ = 0.98 (d, J = 6.7 Hz, 3H), 2.43 (dd, J = 17.2 Hz, 4.8 Hz, 
1H), 2.81 (m, 1H), 3.03 (dd, J = 17.2 Hz, 13.4 Hz, 1H), 3.62 (s, 3H), 3.95 (s, 3H), 4.02 
(s, 3H), 5.54 (s, 1H), 6.09 (d, J = 5.2 Hz, 1H). 13C NMR (175 MHz, CDCl3) δ = 14.4, 
36.6, 40.2, 56.5, 56.8, 57.3, 90.1, 91.0, 105.0, 105.0, 132.4 (d, J = 238.0 Hz), 154.7 (d, J
= 1.8 Hz), 157.4 (d, J = 7.0 Hz), 160.3 (d, J = 8.8 Hz), 170.9, 192.4 (d, J = 2.4 Hz), 
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197.1. 19F NMR (470 MHz, CDCl3) δ = -171.3 (d, J = 5.2 Hz) (See Table 13 and Figure 
29-33); HRESIMS m/z 337.1079 [M+H]+ (calc’d for C17H18FO6 337.1082). 
 Fluorination of 7-dechloro-5'-hydroxygriseofulvin (4). 7-dechloro-5'-
hydroxygriseofulvin (4) (6.2 mg, 0.018 mmol) and Selectfluor (9.8 mg, 0.027 mmol) 
were reacted via the general method. After purification using preparative HPLC eluting 
with a linear gradient from 30% to 50% CH3CN in H2O (0.1% HCOOH) over 30 min to 
obtain compounds 11 ( tR =16 min), and 12 (tR =14 min).  
 5-Fluoro-5'-hydroxy-7-dechlorogriseofulvin ((2S,5'R,6'R)-5-fluoro-5'-hydroxy-
2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 11): 
White solid; [α]D27 +240 (c 0.05, MeOH); 1.7 mg (27 % yield, 35 % yield based on 
recovered starting material); 1H NMR (700 MHz, CDCl3) δ = 1.10 (d, J = 6.9 Hz, 3H), 
2.54 (dq, J = 12.0 Hz, 6.9 Hz, 1H), 3.67 (s, 3H), 3.98 (s, 3H), 4.21 (d, J = 3.6 Hz, 3H), 
4.67 (d, J = 12.0 Hz, 1H), 5.61 (s, 1H), 6.36 (d, J = 5.4 Hz, 1H). 13C NMR (175 MHz, 
CDCl3) δ = 11.1, 43.7, 57.1, 57.1, 62.1 (d, J = 6.7 Hz), 71.4, 89.1, 90.4, 101.9, 105.5 (d, 
J = 1.4 Hz), 139.6 (d, J = 241.6 Hz), 145.1 (d, J = 7.9 Hz), 158.9 (d, J = 11.2 Hz), 170.5, 
171.7, 193.4 (d, J = 3.3 Hz), 197.5. 19F NMR (470 MHz, CDCl3) δ = -162.7 (dq, J = 5.4 
Hz, 3.6 Hz) (See Table 14 and Figures 34-38); HRESIMS m/z 353.1027 [M+H]+ (calc’d 
for C17H18FO7 353.1031). 
 7-Fluoro-5'-hydroxy-7-dechlorogriseofulvin ((2S,5'R,6'R)-7-fluoro-5'-hydroxy-
2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; 12): 
White solid;[α]D27 +270 (c 0.03, MeOH); 1.0 mg (16% yield, 21 % yield based on 
recovered starting material); 1H NMR (700 MHz, CDCl3) δ = 1.13 (d, J = 6.3 Hz, 3H), 
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2.60 (dq, J = 12.0 Hz, 6.3Hz, 1H), 3.66 (s, 3H), 3.95 (s, 3H), 4.03 (s, 3H), 4.68 (d, J = 
12.0 Hz, 1H), 5.61 (s, 1H), 6.10 (d, J = 5.1 Hz, 1H); 13C NMR (175 MHz, CDCl3) δ =  
11.1, 43.7, 56.6, 57.1, 57.3, 71.4, 90.2, 91.2, 101.8, 104.9, 132.2 (d, J = 237.0 Hz), 154.8 
(d, J = 1.8 Hz), 157.6 (d, J = 8.8 Hz), 160.3 (d, J = 10.5 Hz), 171.5, 192.4 (d, J = 2.7 
Hz), 197.4. 19F NMR (470 MHz, CDCl3) δ = -171.1 (d, J = 5.1 Hz) (See Table 15 and 
Figures 39-43); HRESIMS m/z 353.1022 [M+H]+ (calc’d for C17H18FO7 353.1031). 
 Cytotoxicity assay. Human melanoma cancer cells (MDA-MB-435), human 
breast cancer cells (MDA-MB-231) and human cancer cells (OVCAR3) were procured 
from the American Type Culture Collection (Manassas, VA). The cell lines were 
cultivated in RPMI 1640 medium, supplemented with fetal bovine serum (10%), 
penicillin (100 units/mL), and streptomycin (100 µg/mL); and grown at 37°C under 5% 
CO2. Huh7.5.1 cells were cultured in DMEM medium as previously described.100 Cells in 
log-phase growth were harvested by trypsinization followed by two washing to remove 
all traces of enzyme. Cells were seeded in 96-well cl ar, flat-bottom plate (Corning) at a 
density of 5,000 cells per well, and each plate wasincubated overnight at 37°C under 5% 
CO2. Samples dissolved in DMSO were diluted and added to the appropriate wells to 
give final concentrations of 20 and 2 µg/mL (20, 4, 0.8, 0.16, and 0.032 µM for pure 
compounds) with a total volume of 100 µL and 0.5% DMSO. The cells with the test 
samples were then incubated for 72 h at 37 °C. Cell viability was examined using a 
commercial absorbance assay (Cell titer 96® Aqueous One Solution Cell Proliferation 
Assay, Promega Corp, Madison, WI). For Huh7.5.1 cells, viability was determined by 
measuring ATP levels in cells using the ATPlite kit (Perkin Elmer, Waltham, MA) as 
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previously described.101 Results are expressed as percent survival relative to the solvent 
(DMSO) control. 
 Antifungal assay. The test fungal isolate Microsporum gypseum was kept at the 
Fungal Culture Collection at the Department of Chemistry and Biochemistry at the 
University of North Carolina at Greensboro. The test isolate was maintained on Saboraud 
dextrose agar plates at rt and sub-cultured monthly throughout this study. The test 
compounds were dissolved in DMSO and 5 µL were loaded onto a 6 mm filter paper disk 
to obtain the desired 25 µg sample concentration per disk. Antimycotic activity was 
carried out by the agar disk diffusion method.102,103 Following growth of the fungi, the 
conidia were harvested in sterile distilled deionized water. The inoculum was adjusted to 
0.5-1.0 OD (~105 cells/ mL) at 600 nm. Mueller-Hinton agar supplemented with 2% 
glucose and 0.5 µg/ml methylene blue was then seeded with 100 uL of the inoculum. 
Disks impregnated with the test agent were aseptically added onto the surface of the 
inoculated plates.  The sensitivity of the microorganism to the compounds was 
determined after 5 d by measuring the diameter (in mm) of the zones of inhibition around 
the disks. 
 Principal component analysis. The structures and SMILES where generated 
with ChemDraw and 11 molecular properties were calcul ted using QikProp (version 
3.5)104. The calculated properties can be divided in three main groups: electronic, surface, 
and solubility descriptors. The electronic descriptors were: calculated electron affinity 
EA (eV), predicted polarizability (QPpolrz), electrotopological state (Estate) and dipole 
moment of the molecule (dipole). The surface descriptors were:  total solvent accessible 
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area (SAS), hydrophilic component of the SASA (FISA), carbon and attached hydrogen 
component of the SASA (PISA), Van der Waals surface area of polar nitrogen and 
oxygen atoms (PSA), and solvent-accessible surface area of fluorine atoms (SAFluorine). 
The solubility descriptors were: free energy of solvation in hexadecane (QPlogPC16) and 
predicted aqueous solubility (QPlogS). To generate a visual representation of the 
chemical space based on these properties, a principal component analysis was performed 
using Molecular Operating Environment (version 2014. 8)105, and Data Warrior (version 
4.2.2)106. 
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Table 3. In Vitro Cytotoxicity of X. cubensis (MSX48662) Extract  
Against Three Human Cancer Cell Lines. 
 
Sample MDA-MB-435a MDA-MB-231b OVCAR3c 
 20 
µg/mL 
2 
µg/mL 
20 
µg/mL 
2 
µg/mL 
20 
µg/mL 
2 
µg/mL 
MSX48662 25 28 50 62 23 59 
a melanoma cancer cells; b human breast cancer cells;  
c human ovarian cancer cells 
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Table 4. NMR Data for Griseofulvin (1) in CDCl 3. 
Position δCa type δH, mult (J in Hz)b HMBC 
2 90.9 C   
3 192.6 C   
3a 105.2 C   
4 157.9 C   
5 89.5 CH 6.13, s 3, 3a, 4, 6, 7 
6 164.7 C   
7 97.3 C   
7a 169.6 C   
2´ 170.9 C   
3´ 105.0 CH 5.53, s 2, 2´, 4´, 5´ 
4´ 197.2 C   
5´ 40.1 CH2 α 2.42, dd (16.8, 4.6) 
β 3.03, dd (16.8, 13.4) 
2, 3´, 4´, 6´, 6´-Me 
2, 4´, 6´, 6´-Me 
6´ 36.5 CH 2.84, m 2, 3, 5´, 6´-Me 
6´-Me 14.4 CH3 0.96, d (6.8) 2, 3, 5´, 6´ 
4-OMe 56.5 CH3 3.98, s 4 
6-OMe 57.1 CH3 4.03, s 6 
2´-OMe 56.8 CH3 3.61, s 3a, 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
Figure 6. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Griseofulvin (1) in CDCl3. 
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Table 5. NMR Data for 5´-Hydroxygriseofulvin (2) in CDCl 3. 
Position δCa type δH, mult (J in Hz)b HMBC 
2 91.2 C   
3 192.6 C   
3a 105.2 C   
4 158.0 C   
5 89.7 CH 6.14, s 3a, 4, 6, 7 
6 165.0 C   
7 97.4 C   
7a 169.8 C   
2´ 171.5 C   
3´ 101.8 CH 5.61, s 2, 2´, 5´ 
4´ 197.5 C   
5´ 71.5 CH 4.68, d (12.2)  
6´ 43.6 CH 2.64,dq (12.2, 6.7) 2, 5´ 
6´-Me 11.1 CH3 1.11, d (6.7) 2, 5´, 6´ 
4-OMe 56.6 CH3 3.99, s 4 
6-OMe 57.2 CH3 4.04, s 6 
2´-OMe 57.1 CH3 3.65, s 2´ 
a 175 MHz, b 700 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
   
 
 
 
Figure 7. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 5´-
Hydroxygriseofulvin (2) in CDCl3. 
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Table 6. NMR Data for 7-Dechlorogriseofulvin (3) in CDCl3. 
Position δCa type δH, mult (J in Hz)b HMBC 
2 90.0 C   
3 192.7 C   
3a 104.4 C   
4 159.2 C   
5 93.5 CH 6.03, d (1.9) 3, 3a, 4, 6, 7 
6 170.5 C   
7 88.6 CH 6.23, d (1.9) 3a, 5, 6, 7a 
7a 176.2 C   
2´ 171.5 C   
3´ 104.9 CH 5.53, s 2, 2´, 4´, 5´ 
4´ 197.6 C   
5´ 40.2 CH2 α 2.39, dd (16.8, 4.7) 
β 3.03, dd (16.8, 13.4) 
2, 3´, 4´, 6´,  6´-Me,  
6´ 36.7 CH 2.74 (m) 2, 3, 2´, 4´, 5´, 6´-Me 
6´-Me 14.4 CH3 0.94, d (6.6) 2, 4´, 5´, 6´ 
4-OMe 56.2 CH3 3.90, s 4 
6-OMe 56.2 CH3 3.89, s 6 
2´-OMe 56.8 CH3 3.61, s 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
Figure 8. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 7-
Dechlorogriseofulvin (3) in CDCl3. 
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Table 7. NMR Data for 7-Dechloro-5´-hydroxygriseofulvin (4) in CDCl3. 
Position δCa   type δH, mult (J in Hz)b HMBC 
2 90.5   C   
3 192.6   C   
3a 104.4   C   
4 159.3   C   
5 93.7   CH 6.06, d (1.1) 3a, 4, 6, 7 
6 170.8   C   
7 88.6   CH 6.22, d (1.1) 3a, 5, 6, 7a 
7a 176.3   C   
2´ 172.1   C   
3´ 101.7   CH 5.61, s 2, 2´, 4´, 5´ 
4´ 197.8   C   
5´ 71.5   CH 4.71, d (12.1) 4´, 6´, 6´-Me 
6´ 43.9   CH 2.55, dq (12.1, 6.6) 2, 3, 5´, 6´-Me 
6´-Me 11.2   CH3 1.11, d (6.6) 2, 5´, 6´ 
4-OMe 56.3   CH3 3.92, s 4 
6-OMe 56.3   CH3 3.91, s 6 
2´-OMe 57.1   CH3 3.66, s 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
Figure 9. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) 
Spectra of 7-Dechloro-5´-hydroxygriseofulvin (4) in CDCl3. 
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Figure 10. 1H-13C Edited-HSQC Spectrum of 7-Dechloro-5´-hydroxygriseofulvin (4). 
 
 
 
Figure 11. HMBC Spectrum of 7-Dechloro-5´-hydroxygriseofulvin (4). 
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Table 8. NMR Data for 6-O-desmethyl-7-dechlorogriseofulvin (5) in CDCl3. 
Position δCa type δH, mult (J in Hz)b HMBC 
2 90.0 C   
3 192.6 C   
3a 104.1 C   
4 159.9 C   
5 93.6 CH 6.05, d (1.9) 3, 3a, 4, 5, 6 
6 167.9 C   
7 91.7 CH 6.20, d (1.9) 3a, 6, 7, 7a 
7a 175.8 C   
2´ 172.2 C   
3´ 104.7 CH 5.55, s 2, 2´, 4´, 5´ 
4´ 198.4 C   
5´ 40.1 CH2 α 2.43, dd (16.7, 4.8) 
β 3.08, dd (16.7, 13.2) 
2, 3´, 4´ 
4´, 6´, 6´-Me 
6´ 36.7 CH 2.76, dqd (13.2, 6.7, 4.8) 2, 3 
6´-Me 14.4 CH3 0.97, d (6.7) 2, 5´, 6´ 
4-OMe 56.3 CH3 3.90, s 4  
2´-OMe 56.9 CH3 3.64, s 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
Figure 12. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 6-
O-desmethyl-7-dechlorogriseofulvin (5) in CDCl3. 
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Table 9. NMR Data for 6-O-desmethylgriseofulvin (6) in CDCl3. 
Position δCa type δH, mult (J in Hz)b HMBC 
2 91.2 C   
3 192.2 C   
3a 105.4 C   
4 158.0 C   
5 93.6 CH 6.25, s 3, 3a, 4, 6, 7  
6 161.8 C   
7 95.2 C   
7a 169.9 C   
2´ 170.7 C   
3´ 105.0 CH 5.55, s 2, 2´, 4´, 5´ 
4´ 197.2 C   
5´ 40.1 CH2 α 2.44, dd (16.6, 4.7) 
β 3.04, dd (16.6, 13.3) 
2, 3´, 6´ 
4´, 6´, 6´-Me,   
6´ 36.5 CH 2.83, dqd (13.3, 6.7, 4.7) 6´-Me, 5´, 2, 3 
6´-Me 14.4 CH3 0.97, d (6.7) 6´, 5´, 2 
4-OMe 56.6 CH3 3.92, s 4 
2´-OMe 56.8 CH3 3.63, s 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 6-
O-desmethylgriseofulvin (6) in CDCl3. 
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Table 10. NMR Data for Compound 7 in CDCl3. 
Position δC mult (J in Hz)a type δH, mult (J in Hz)b HMBC 
2 90.6 C   
3 193.5,d (3.4) C   
3a 108.0 C   
4 144.7, d (9.0) C   
5 142.9, d (244.3) C   
6 153.9, d (12.1) C   
7 103.4 C   
7a 164.9 C   
2´ 170.5 C   
3´ 105.2 C 5.56, s 2, 2´, 4´, 5´ 
4´ 196.8 C   
5´ 40.0 CH2 α 2.45, dd (16.7, 4.4) 
β 2.98, dd (16.7, 13.3) 
3´ 
2, 4´, 6´, 
6´-Me 
6´ 36.6 CH 2.85, dqd (13.3, 6.7, 4.4) 2, 3, 6´, 6´-
Me  
6´-Me 14.4 CH3 0.95, d (6.7) 2, 5´, 6´  
4-OMe 62.6, d (6.0) CH3 4.20, d (3.1) 4 
6-OMe 62.1, d, (7.0) CH3 4.17, d (3.1) 6 
2´-OMe 56.9 CH3 3.64, s 2´ 
a 100 MHz, b 400 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
Figure 14. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Compound 7 in CDCl3. 
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Figure 15. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compound 7 in CDCl3. 
 
 
Figure 16. 13C NMR and 19F-13C HMQC Spectrum of Compound 7 in CDCl3. 
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Figure 17. 1H-13C Edited-HSQC Spectrum of Compound 7 in CDCl3.  
 
 
 
Figure 18. 1H-13C HMBC Spectrum of Compound 7 in CDCl3. 
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Table 11. NMR Data for Compounds 8a/8b in CDCl3. 
 8a 8b 
Position δC, mult  
(J in Hz)a 
δH, mult  
(J in Hz)b 
δC, mult  
(J in Hz)a 
δH, mult  
(J in Hz)b 
HMBC 
2 94.1  94.1   
3 191.8  191.7   
3a 110.1, d (3.0)  110.0, d (3.0)   
4 176.9, d (2.0)  176.9, d (2.0)   
5 102.0, d (2.0) 5.55, d (1.8) 102.0, d (2.0) 5.55, d (1.8) 3, 3a, 4, 6  
6 162.8, d (19.1)  162.8, d (19.1)   
7 94.1, d (252.3)  94.0, d (254.3)   
7a 185.3, d (21.0)  185.4, d (21.0)   
2´ 168.1  167.7   
3´ 105.4 5.58, s 105.5 5.58, s 2, 2', 4', 5' 
4´ 195.8  195.8   
5´ 39.7 α 2.46, dd 
(16.1, 4.2) 
β 2.97, m 
39.7 α 2.46, dd 
(16.1, 4.2) 
β 2.97, m 
4', 6', 6'-Me 
 
6´ 36.1 2.89, m 36.5 2.95, m 2, 3, 5', 6'-Me 
6´-Me 14.1 1.00, d (6.3) 14.1 1.06, d (6.5) 2, 5', 6' 
6-OMe 57.8 3.94, s 57.8 3.94, s 5, 6 
2´-OMe 57.1 3.69, s 57.2 3.67, s 2' 
a 100 MHz, b 500 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
(8a/8b) in CDCl3. 
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Figure 20. 1H-13C Edited-HSQC Spectrum of Compounds 8a/8b in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. 1H-13C HMBC Spectrum of Compounds 8a/8b in CDCl3. 
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Figure 22. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compounds 8a/8b in 
CDCl3. 
 
 
 
Figure 23. 13C NMR and 19F-13C HMQC Spectrum of Compounds 8a/8b in CDCl3. 
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Table 12. NMR Data for Compound 9 in CDCl3. 
Position δC, mult (J in Hz)a type δH, mult (J in Hz)b HMBC 
2 90.0 C   
3 193.4, d (3.0) C   
3a 105.5, d (1.2) C   
4 145.0, d (8.8) C   
5 139.6, d (237.5) C   
6 158.6, d (11.3) C   
7 89.8 CH 6.37, d (5.2) 3a, 5, 6, 7a 
7a 170.4 C   
2‘ 171.1 C   
3‘ 105.0 C 5.55, s 2, 2‘, 4‘, 5‘ 
4‘ 197.2 C   
5‘ 40.1 CH2 α 2.75, dd (17.2, 4.6) 
β 3.02, dd (17.2, 13.2) 
2, 4‘, 6‘, 6‘-Me 
2, 3‘, 4‘, 6‘, 6‘-Me 
6‘ 36.7 CH 2.75, m 2, 3, 2‘, 4‘ 
6‘-Me 14.4 CH3 0.95, d (6.9) 2, 5‘, 6‘ 
4-OMe 62.1, d (7.5) CH3 4.20, d (3.3) 4 
6-OMe 57.0 CH3 3.98, s 6 
2‘-OMe 56.8 CH3 3.63, s 2‘ 
a 125 MHz, b 500 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. 1H NMR (500 MHz; Top) and 13C NMR (125 MHz; Bottom) Spectra of 
Compound 9 in CDCl3. 
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Figure 25. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compound 9 in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. 13C NMR and 19F-13C HMQC Spectrum of Compound 9 in CDCl3. 
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Figure 27. 1H-13C Edited-HSQC Spectrum of Compound 9 in CDCl3. 
 
 
 
Figure 28. 1H-13C HMBC Spectrum of Compound 9 in CDCl3. 
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Table 13. NMR Data for Compound 10 in CDCl3. 
Position δC, mult (J in Hz)a type δH, mult (J in Hz)b HMBC 
2 91.0 C   
3 192.4, d (2.4) C   
3a 105.0 C   
4 154.7, d (1.8) C   
5 90.1 CH 6.09, d (5.2) 3, 3a, 4, 6, 7  
6 157.4, d (7.0) C   
7 132.4, d (238.0) C   
7a 160.3, d (8.8) C   
2´ 170.9 C   
3´ 105.0 CH 5.54, s 2, 2´, 5´ 
4´ 197.1 C   
5´ 40.2 CH2 α 2.43, dd (17.2, 4.8) 
β 3.03, dd (17.2, 13.4) 
2, 3´, 4´, 6´, 6´-
Me 
2, 4´, 6´, 6´-Me 
6´ 36.6 CH 2.81, m 2, 3, 2´, 4´, 5´, 6´-Me
6´-Me 14.4 CH3 0.98, d (6.7) 2, 5´, 6´  
6-OMe 57.3 CH3 4.02, s 6 
4-OMe 56.5 CH3 3.95, s 4 
2´-OMe 56.8 CH3 3.62, s 2´ 
a 175 MHz, b 700 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 
Compound 10 in CDCl3. 
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Figure 30. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compound 10 in 
CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. 13C NMR and 19F-13C HMQC Spectrum of Compound 10 in CDCl3. 
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 Figure 32. 1H-13C Edited-HSQC Spectrum of Compound 10 in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. 1H-13C HMBC Spectrum of Compound 10 in CDCl3. 
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Table 14. NMR Data for Compound 11 in CDCl3. 
Position δC, mult (J in Hz)a type δH, mult (J in Hz)b HMBC 
2 90.4 C   
3 193.4, d (3.3) C   
3a 105.5, d (1.4) C   
4 145.1, d (7.9) C   
5 139.6, d (241.6) C   
6 158.9, d (11.2) C   
7 89.1 CH 6.36, d (5.4) 3a, 4, 5, 6, 7a 
7a 170.5 C   
2‘ 171.7 C   
3‘ 101.9 CH 5.61, s 2, 2´, 4´, 5´ 
4‘ 197.5 C   
5‘ 71.4 CH 4.67, d (12.0) 4´, 6´, 6´-Me 
6‘ 43.7 CH 2.54, dq (12.0, 6.9) 2, 3, 5´, 6´-Me 
6‘-Me 11.1 CH3 1.10, d (6.9) 2, 5´, 6´ 
4-OMe 62.1, d (6.7) CH3 4.21, d (3.6) 4 
6-OMe 57.1 CH3 3.98, s 6 
2‘-OMe 57.1 CH3 3.67, s 2´ 
a 175 MHz, b 700 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 
Compound 11 in CDCl3. 
59 
 
 
Figure 35. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compound 11 in 
CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. 13C NMR and 19F-13C HMQC Spectrum of Compound 11 in CDCl3. 
d, 5.4 Hz
d, 3.6 Hz
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Figure 37. 1H-13C Edited-HSQC Spectrum of Compound 11 in CDCl3. 
 
 
 
Figure 38. 1H-13C HMBC Spectrum of Compound 11 in CDCl3. 
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Table 15. NMR Data for Compound 12 in CDCl3. 
Position δC, mult (J in Hz)a type δH, mult (J in Hz)b HMBC 
2 91.2 C   
3 192.4, d (2.7) C   
3a 104.9 C   
4 154.8, d (1.8) C   
5 90.2 CH 6.10, d (5.1) 3, 3a, 4, 6, 7 
6 157.6, d (8.8) C   
7 132.2, d (237.0) C   
7a 160.3, d (10.5) C   
2‘ 171.5 C   
3‘ 101.8 CH 5.61, s 2, 2´, 4´, 5´ 
4‘ 197.4    
5‘ 71.4 CH 4.68, d (12.0) 4´, 6´, 6´-Me 
6‘ 43.7 CH 2.60, dq (12.0, 6.3) 2, 3, 2´, 4´, 5´, 6´-Me 
6‘-Me 11.1 CH3 1.13, d (6.3) 2, 5´, 6´ 
6-OMe 57.3 CH3 4.03, s 6 
4-OMe 56.6 CH3 3.95, s 4 
2‘-OMe 57.1 CH3 3.66, s 2´ 
a 175 MHz, b 700 MHz Jeol NMR Spectrometer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 
Compound 12 in CDCl3. 
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Figure 40. 1H NMR (Top) and 19F NMR (Bottom) Spectra of Compound 12 in 
CDCl3. 
 
 
Figure 41. 13C NMR and 19F-13C HMQC Spectrum of Compound 12 in CDCl3.   
d, 5.1 Hz 
d, 5.1 Hz
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Figure 42. 1H-13C Edited-HSQC Spectrum of Compound 12 in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. 1H-13C HMBC Spectrum of Compound 12 in CDCl3. 
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Table 16. In Vitro Cytotoxicity of Compounds 1-12 Against Three Human  
Cancer Cell Lines.a 
Compound IC50 (µM) 
MDA-MB-435c MDA-MB-231d OVCAR3e 
1 6.4 µM inactive 48.5 µM 
2 inactive inactive inactive 
3 inactive inactive inactive 
4 inactive inactive inactive 
5 inactive inactive inactive 
6 inactive inactive inactive 
7 inactive inactive inactive 
8a/8b inactive inactive inactive 
9 inactive inactive inactive 
10 22.0 µM inactive inactive 
11 inactive inactive inactive 
12 inactive inactive inactive 
Vinblastineb                 0.5 nM 8.8 nM     1.8 nM            
aA compound is indicated as inactive if no activity was observed at 50 µM. 
bPositive control with inhibition of cell growth expressed as IC50 (nM). 
cHuman melanoma cancer cells 
dHuman breast cancer cells 
eHuman ovarian cancer cells 
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Table 17. Antifungal Activity of Compounds 1-12 Against 
Microsporum gypseum. 
 
Compound Inhibition Zone Diameter (mm)a 
1 35 ±1 
2 0 
3 0 
4 0 
5 0 
6 0 
7 23 ± 1 
8a/8b 0 
9 0 
10 34 ± 1 
11 0 
12 0 
Commercial Griseofulvin 35 ± 2 
aInhibition diameter expressed as the mean of four replicates ± 
standard deviation 
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Table 18. Cytotoxic Activity of Griseofulvin (1) and its Analogues (7-12)  
Against Human Hepatoma (Huh7.5.1) Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound IC50 (µM) 
1 12.6 
2 180.6 
3 ~6843 
4 ~723.0 
5 >300 
6 9.0 
7 82.7 
9 290.4 
10 23.9 
11 155.9 
12 198.3 
67 
 
 
Figure 44. Cytotoxic Activity of Griseofulvin (1) and its Analogues (7-12) Against 
Human Hepatoma (Huh7.5.1) Cells. 
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Figure 45. Visual Representation of the Chemical Space of Griseofulvin (1, 
Red), Structurally Related Fungal Analogues (2-6, Green) and Fluorinated 
Semisynthetic Derivatives (7-12, Blue). The substructures found on the derivatives 
and natural products but not on griseofulvin’s structure are depicted in red. This 2D 
plot was generated with the principal component analysis of 11 descriptors. The first 
two principal components recovered 68% of the covariance. The electron affinity 
(EA(eV)) and electropological state (Estate) had the highest contribution to the first 
principal component, while predicted aqueous solubility (QPlogS) had the highest 
contribution to the second principal component. 
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CHAPTER III 
ACETOPHENONE DERIVATIVES FROM A FRESHWATER FUNGAL ISOLATE 
OF RECENTLY DESCRIBED LINDGOMYCES MADISONENSIS (G416) 
 
This chapter has been published in the journal Phytochemistry and is presented in 
that style. Noemi D. Paguigan, Huzefa A. Raja, Cynthia S. Day, and Nicholas H. 
Oberlies. Phytochemistry (2016) 126, 59-65. 
 
 
The exploration of freshwater ascomycetes, which have undergone only limited 
investigation, may provide opportunities both to characterize new genera/species of fungi 
and to uncover new chemical diversity. In this study, seven acetophenone derivatives (1-
7), madisone (1), 4´-methoxymadisone (2), dehydromadisone (3), 2´´-methoxymadisone 
(4), dihydroallovisnaginone (5), dimadisone (6), and 4´-methoxydimadisone (7) were 
characterized from an organic extract of a recently described Lindgomyces madisonensis 
(G416) culture, which was isolated from submerged wood collected in a stream in North 
Carolina. Compounds 1, 3, 4, 6, and 7 have not been reported previously, while 2 and 5 
were isolated for the first time as natural products. The structures were assigned on the 
basis of NMR and HRESIMS data, with the structure of 1 supported by x-ray 
crystallography. The antimicrobial activities of compounds 1, 2, and 5 were evaluated 
against a panel of bacteria and fungi. A heat map an lysis of the surface of a G416 
culture showed that most of the isolated compounds concentrated in the guttate compared 
with the vegetative mycelium of the fungus.
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Introduction  
Fungi represent a highly diverse group of organisms, and even though there exists 
an estimated 5.1 million species, less than 100 thousand have been cultivated and 
described,107 and only a fraction of those have been studied with respect to their 
chemistry.108 Freshwater ascomycetes are an ecological group that occur on submerged 
substrates in fresh water and play an important role as decomposers in these 
habitats.39,109,110 The number of described ascomycetes has increased dramatically over 
the past 25 years. Shearer (1993) reported about 200 species from freshwater habitats 
worldwide; that number doubled to 414 in a 2001 review.111 Currently, about 640 
freshwater ascomycetes have been described.110 While knowledge regarding the 
distribution patterns and taxonomy has increased for this ecological group of fungi due to 
intensive collection over the last two decades, their chemistry, particularly regarding 
secondary metabolites, has had limited investigation.112-117 As of 2011, approximately 
127 chemical structures had been reported from about 30-40 freshwater fungal 
species.11,118,119 To ameliorate this knowledge gap, we have initiated studies on the 
chemical mycology of freshwater ascomycetes in North Carolina, USA,118-122 
representing the first systematic study of freshwater scomycetes from this region of 
North America. Ongoing investigations led to the isolation of five new acetophenones (1,
3, 4, 6, and 7), along with 4´-methoxymadisone (2) and dihydroallovisnaginone (5), from 
a fungal isolate recently described as Lindgomyces madisonensis (G416) Raja & 
Oberlies.123 A heat map analysis by in situ sampling via droplet-liquid microjunction-
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surface sampling probe (droplet-LMJ-SSP) of a G416 culture showed that the isolated 
compounds were more abundant in the guttate compared to the fungal mycelium. 
Results and Discussion 
 Structural characterization and bioactivity of compounds 1-7. A culture of L. 
madisonensis (G416) was isolated from decomposing wood collected in the central 
Piedmont region of North Carolina. The fungus was cultured by solid-substrate 
fermentation on rice, and this material was extracted with 1:1 CHCl3-CH3OH. The 
resulting extract was subjected to partitioning with organic solvents followed by 
purification using flash chromatography yielding five fractions. These fractions were 
further purified using preparative HPLC, leading to the isolation of compounds 1-7 
(Figure 46). The structures of these were established by analysis of spectroscopic (NMR) 
and spectrometric (HRESIMS) data. 
 
 
Figure 46. Structures of Compounds 1-7 
 
 
On the basis of HRESIMS and NMR data (Table 19, Figure 49), compound 1 was 
found to have the molecular formula C11H14O5 (five degrees of unsaturation). The IR 
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spectrum of 1 showed absorption bands at 2972 and 1610 cm-1, indicative of an aromatic 
ring with chelated hydroxy and carbonyl moieties; these functionalities were supported 
by the observed UV absorption maxima at 306 and 237 nm. 13C NMR and HSQC data, 
indicated 11 carbon signals, which were attributed to six aromatic carbons (five 
nonprotonated and one protonated), one ketone carbonyl, and four carbon signals located 
in the aliphatic region of the spectrum. Furthermore, chemical shift data indicated that 
three of the aromatic carbons were oxygenated (δC 163.3, 166.1, 164.7 for C-6´, C-2´, and 
C-4´, respectively). The downfield region of the 1H NMR spectrum of 1 exhibited a 
singlet at δH 5.98 that integrated for one aromatic proton, as expected for a penta-
substituted benzene ring. Based on the 1H NMR data (Table 19), the structure of 1 had 
one isolated methyl group (δH 2.55, singlet), one methoxy, and a hydroxyethyl group. 
The connections between the subunits were deduced from key HMBC correlations 
(Figure 47), including those of H-5´ to C-6´, C-1´, C-3´, and C-4´; from the methoxy to 
C-6´; from the isolated methyl H3-2 to C-1´; and from H2-1´´ and H2-2´´ of the 
hydroxyethyl group to C-2´, C-3´, and C-4´, and to C-3´, respectively. In further efforts to 
verify the locations of subunits on the aromatic ring, 1H NMR data for 1 were recorded in 
CDCl3, revealing a singlet resonance at δH 14.58 that was not observed when recorded in 
CD3OD (Figure 56). This result was consistent with the downfield shift associated with 
intramolecular H-bonding between the proton of the C-2´ hydroxy group and the oxygen 
of the C-1 carbonyl. The structure of 1, recrystallized from CH3OH, was unambiguously 
assigned by x-ray crystallography (Figure 71) and ascribed the trivial name, madisone.  
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Table 19. 1H NMR and 13C NMR Data for Compounds 1-3 in CD3OD. 
 
 
Compound 2 was assigned the molecular formula C12H16O5 (five degrees of 
unsaturation) on the basis of HRESIMS and NMR data. The NMR spectral data for 2 
(Table 19) were nearly identical to that of compound 1, but with additional signals for a 
second methoxy group, which were consistent with a 14 amu mass difference. A key 
HMBC correlation was observed from the methoxy group to C-4´, confirming its 
connectivity and establishing the structure of 2 (Figures 46, 47, and 58). Compound 2 
was first described by Wootton as one of the intermediates in an attempted synthetic 
oxidative approach to LL-D253α.124 Their data were acquired in CDCl3; the data herein 
 1a 2a 3a 
Position δC 
δH, mult 
(J in Hz) 
δC 
δH, mult 
(J in Hz) 
δC 
δH, mult 
(J in Hz) 
1 204.2   204.8   204.2  
2  33.1  2.55, s 33.4   2.58, s 33.1   2.56, s 
1´ 105.9   106.6  105.9   
2´ 166.1   164.9  165.6   
3´ 105.6   106.6  111.2  
4´ 164.7  165.7  164.0   
5´   91.2  5.98, s  87.4 6.16, s 91.0  5.98, s 
6´ 163.3   163.9  162.8  
1´´ 26.7 2.82, t (7.6) 26.6 2.82, t 
(7.6) 
16.3 2.54, q 
(7.3) 
2´´ 62.0 3.61, t (7.6) 61.8 3.55, t 
(7.6) 
13.8 1.04,  t 
(7.3) 
4´- OCH3     n/a - *56.2 3.91, s     n/a - 
6´- OCH3 55.9  3.84, s *56.1  3.93, s 55.8  3.84, s 
2´´-OCH3 n/a - n/a - n/a - 
a  Data were collected at 400 MHz (1H) or 100 MHz (13C). 
b  Data were collected at 700 MHz (1H) or 175 MHz (13C). 
* May be interchanged. 
# Value deduced from HMBC 
n/a Not applicable 
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(Figure 56) were consistent with the literature with one caveat. It is considered that there 
was an error in the previous assignment of the C-3´chemical shift value in the literature. 
Thus, we have included the NMR shift assignments of 2. As this is the first report of the 
isolation of 2 from a natural source, it was given the trivial name 4´-methoxymadisone.                                         
 
 
Figure 47. Key HMBC Correlations of Compounds 1, 5, and 7. 
 
 
The HRESIMS and NMR data (Table 19) established the molecular formula for 
compound 3 as C11H14O4 (five degrees of unsaturation). Comparison of these data to 
those of compound 1 indicated the loss of the hydroxy moiety at C-2´´, which was 
consistent with the associated changes in the shifts and the multiplicities of H2-1´´ (δH 
2.54, quartet, 7.3 Hz) and H3-2´´ (δH 1.04, triplet, 7.3 Hz); it also accounted for the 16 
amu mass difference between these compounds. As such, compound 3 was identified as 
shown (Figure 46) and assigned the trivial name dehy romadisone. 
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Table 20. 1H NMR and 13C NMR Data for Compounds 4-6 in CD3OD. 
 
 The molecular formula of compound 4 was deduced as C12H16O5 (five degrees of 
unsaturation) based on HRESIMS and NMR data (Table 20). The NMR and HRMS of 4
suggested structural similarities to 1. However, 4 had an additional methoxy unit (δC/δH 
58.5/3.36) as evidenced by a 14 amu difference in the HRMS between 1 and 4. Further 
analysis of the 1- and 2-D NMR data indicated that e 2´´-OH in 1 was replaced with a 
 4b 5a 6a 
Position δC 
δH, mult  
(J in Hz) 
δC 
δH, mult 
(J in Hz) 
δC 
δH, mult  
(J in Hz) 
1 
204.1  204.
4 
 204.2  
2 33.0 2.56, s 33.1 2.55, s   33.1 2.56, s 
1´ 
105.9  106.
8 
 105.9  
2´ 
166.1  162.
7 
 166.1  
3´ 
105.4  106.
3 
 105.5  
4´ 
#164.9  169.
3 
 164.7  
5´ 91.4 5.99, s 86.7 6.06, s   91.3 5.99, s 
6´ 
163.4  165.
8 
 163.4  
1´´ 23.4 2.84, t (7.6) 26.6 3.05, t (7.6)   23.6 2.84, t (7.3) 
2´´ 72.6 3.48, t (7.6) 74.4 4.65, t (7.6)   70.6 3.55, t (7.3) 
4´- OCH3 n/a - n/a -     n/a - 
6´- OCH3 
55.9  3.85, s 56.3 3.86, s   
55.7 
3.85, s 
2´´-OCH3 
58.5 3.36, s n/a -     
n/a 
- 
a  Data were collected at 400 MHz (1H) or 100 MHz (13C). 
b  Data were collected at 700 MHz (1H) or 175 MHz (13C). 
* May be interchanged. 
# Value deduced from HMBC 
n/a Not applicable 
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methoxy unit in 4. This substitution was confirmed by the observed more downfield C-
2´´ shift in 4 (δC 72.6) compared to the C-2´´ shift in 1 (δC 62.0). Conversely, C1´´ 
appeared more upfield in 4 compared to 1 at δC 23.4 and δC 26.7, respectively. Moreover, 
an HMBC correlation observed for the methoxy protons to C-2´´ (Figure 47 and Figure 
60) established its connectivity. Thus, the structure of compound 4 was assigned (Figure 
46) and ascribed the trivial name 2´´-methoxymadisone.  
 Compound 5 was found to have the molecular formula C11H12O4 (six degrees of 
unsaturation) on the basis of HRESIMS and NMR data (Table 20). The 1H NMR 
spectrum of 5 exhibited signals that were almost identical to those f 1 but with more 
deshielded H2-1´´ and H2-2´´ resonances at δH 3.05 (triplet, 7.6 Hz) and δH 4.65 (triplet, 
7.6 Hz), respectively. This distinct change in the c mical shift values suggested a 
heterocycle, which also accounted for the additional u saturation and the 18 amu mass 
difference between 1 and 5 (Figure 46). Although this is the first report of the isolation of 
5 from a natural source, Geissman and Hinreiner described it (and named it 
dihydroallovisnaginone) as one of the derivatives in the monomethylation of 4,6-
dihydroxy-5-acetylcoumarane in an attempt to synthesize visnaginone.125 Although NMR 
and HRMS data were not available in 1951, the UV data were consistent with the 
literature. 
 The 1H and 13C NMR data of 6 (Table 20) showed signals that were nearly 
identical to those of 1. However, the HRMS data established the molecular formula to be 
C22H26O9 (ten degrees of unsaturation), which indicated twice as many carbons, along 
with 12 additional hydrogen and four more oxygen atoms relative to the formula of 1.
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Compound 6 was presumed to be a homodimer of 1 with an ether linkage connecting the 
two halves. The HMBC correlation from H2-2´´ (δH 3.55) to C-2´´ (δC 70.6) implied that 
the two symmetrical units of the compound were connected on the hydroxyethyl group 
comprised of C-1´´ and C-2´´ (Figure 47). Therefore, th  structure of 6 was proposed as 
shown in Figure 46 and ascribed the trivial name dimadisone. 
Compound 7 was shown to have the molecular formula C23H28O9 (ten degrees of 
unsaturation) based on analyses of the HRESIMS and NMR data. The 1H and 13C NMR 
data (Table 21) displayed two sets of signals, which ad close resemblance to those  of 
compounds 1 and 2, indicating that 7 was a heterodimer of these compounds. In ring A, 
H-5´ (δH 6.17, s) showed HMBC correlations to C-1´ (δC 106.7), C-3´ (δC 106.6), C-4´ (δC 
165.7), C-6´ (δC 164.0); 6´-OCH3 (δH 3.95, s) to C-6´; H-2 (δH 2.59, s) to C-1´; and 4´-
OCH3 (δH 3.93, s) to C-4´. Furthermore, in ring A, H-1´´ (δH 2.85, m) displayed HMBC 
correlations to C-2´, C-3´, and C-4´.  In ring B, HMBC correlations were observed from 
H-5´´´´ (δH 5.98, s) to C-1´´´´ (δC 106.0), C-3´´´´ (δC 105.7), C-4´´´´ (δC 164.9), C-6´´´´ (δC 
163.4); from 6´´´´-OCH3 (δH 3.85, s) to C-6´´´´; and H-2´´´ (δH 2.56, s) to C-1´´´´ (Figure 
47). Additionally, in ring B, H-1´´´´´ (δH 2.82, m) showed HMBC correlations to C-2´´´´, 
C-3´´´´, and C-4´´´´. The observed key HMBC correlations from H2-2´´ of ring A to C-
2´´´´´  of ring B, and from H2-2´´´´´ (δH 3.55, m) of ring B to C-2´´ (δC 70.3) of ring A, 
indicated that an ether linkage connected the two halves, similar to that of 6. Hence, the 
structure of 7 was established as shown and was ascribed the trivial name 4´-
methoxydimadisone (Figure 46). 
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Table 21. 1H NMR and 13C NMR Data for Compound 7 in CD3OD. 
 
 7 
Position δC  type δH, mult (J in Hz) 
Fragment A    
1 204.8 C  
2 33.3 CH3 2.59, s 
1´ 106.7 C  
2´ 164.9 C  
3´ 106.6 C  
4´ 165.7 C  
5´ 87.5 CH 6.17, s 
6´ 164.0 C  
1´´ 23.4 CH2 2.85, m 
2´´ **70.3 CH2 3.54, m 
4´-OCH3 *56.2  3.93, s 
6´-OCH3 *56.1  3.95, s 
    
Fragment B    
1´´´ 204.2 C  
2´´´ 33.1 CH3 2.56, s 
1´´´´ 106.0 C  
2´´´´ 166.1 C  
3´´´´ 105.7 C  
4´´´´ 164.9 C  
5´´´´ 91.5 CH 5.98, s 
6´´´´ 163.4 C  
1´´´´´ 23.7 CH2 2.82, m 
2´´´´´ **70.5 CH2 3.55, m 
6´´´´-OCH3 55.9   3.85, s 
Data were collected at 700 MHz (1H) or 175 MHz (13C). 
* May be interchanged. 
** May be interchanged. 
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 The structure of 1 was confirmed by x-ray crystallography, and the remaining 
compounds (2-7) were structurally related to it via biosynthetic considerations. In 
particular, the acetophenone moiety was a common motif, n ted through the nearly 
identical NMR data. In addition, when 1H NMR data were acquired in CDCl3, all 
compounds exhibited a singlet resonance in the range from δH 14.00 to δH 14.47 (Figure 
56), indicative of chelation between the hydroxy and carbonyl moieties in all of the 
structures. 
 Compounds 1, 2 and 5 were evaluated for antimicrobial activity against 
Staphylococcus aureus, Escherichia coli, Mycobacterium smegmatis, Candida albicans, 
and Aspergillus niger (Table 25). All the compounds tested had minimal inhibitory 
concentrations greater than 55 µg/mL. Compounds 3, 4, 6, 7 were not evaluated for their 
antimicrobial activity due to the relative paucity of these samples.  
In situ analysis of the concentration of compounds 1-7 in cultures of G416. A 
3-week old culture of G416 growing on PDA media at room temperature (~22-25˚C) 
sealed with parafilm was noted to produce a clear guttate (exudate) (Figure 48). Older 
culture that were grown under the same conditions did not produce any visible guttates. A 
few recent studies have suggested that guttates are a rich source of secondary metabolites, 
although their ecological roles and functions in fugi are still uncertain.126-128 We 
hypothesized that guttates may serve to store secondary metabolites, concentrating them 
for interaction with their environment. To test this, the presence and relative 
concentration of compounds 1-7 were examined in situ using a droplet-liquid 
microjunction-surface sampling probe (droplet-LMJ-SSP), followed by analysis via 
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UPLC-PDA-HRMS-MS/MS, all according to a previously described procedure.129 
Compounds 1, 2 and/or 4 (as they have the same molecular weight), 3, 5, and 6 were 
detected and identified in the guttate based on their retention times, accurate m/z match 
(±5 ppm), and MS/MS fragmentation patterns (Figures 65-69). Compound 1 appeared to 
be the most abundant by L. madisonensis (G416), based on its relative intensity compared 
to 2 and/or 4 and 5, as shown in Figure 48. Although compounds 3 and 6 were identified 
in the guttate by droplet-LMJ-SSP, they were only present in trace amounts compared to 
1. Compounds 1, 2 and/or 4, and trace amounts of 5 were also detected on the outer 
mycelium of G416; however, in all cases, these compounds were more concentrated in 
the guttates. We hypothesize that compound 7 was not detected in the culture, either 
because the fungus biosynthesized it only when grown n rice or after an extended period 
of time. This result was not surprising, as it is well known that variation of media 
conditions can alter the biosynthesis of secondary metabolites in fungi.130,131 An 
alternative hypothesis could be that compound 7 was located inside the mycelium, rather 
than on the surface.132 Overall, the heat profile (Figure 48) suggested that relatively 
higher concentrations of the compounds were present in the guttate in comparison with 
the mycelium. This observation suggested that the fungus could be using the guttates as a 
reservoir to store and/or concentrate secondary metaboli es. Moreover, having a higher 
concentration of 1, in general, corroborated the more traditional natural products 
protocols, where 1 was isolated in the highest yield. With the droplet-LMJ-SSP, the 
spatial distribution and relative concentration of the compounds were evaluated. This 
method can provide additional useful information into the metabolism of the fungus in 
81 
 
situ, which cannot be obtained with traditional isolation techniques. Unfortunately, it was 
not possible to assign a biological activity to these compounds, and thus, their potential 
role in the fungal life cycle is unknown at this time. Further studies to evaluate the 
biological relevance of these compounds, particularly in relation to their concentration in 
guttates, are ongoing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. In situ Droplet-LMJ-SSP Analysis of G416 Culture. (A) A three-week-old 
culture of G416 grown on PDA producing a guttate. (B) Arrow showing a magnified 
view of the guttate. (C) Heat map of compounds 1 (red), 2 (and/or) 4 (blue), and 5 
(green). The height of the bars show the relative amount of signal detected by HRESIMS 
within a 5 ppm mass tolerance for the given compounds. The crosshairs indicate location 
of sampling points of the droplet-LMJ-SSP.  
 
 
Conclusion 
 Lindgomycetaceae is a recently described family of freshwater ascomycetes, and 
little is known about the chemistry produced by species in this family.133 In a previous 
study, the fatty acid, 6E,9E-octadecadienoic acid, and the steroid derivative, ergosterol 
peroxide, were shown to be the major compounds produced by Lindgomyces 
(C) 
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angustiascus.120 Additionally, strains phylogenetically related to the Lindgomycetaceae, 
isolated recently from two different marine habitats produced the newly described 
compound lindgomycin and ascosetin, both of which have polyketide structures.134 The 
isolation and identification of acetophenone derivatives 1-7 from L. madisonensis 
highlights the potential of freshwater ascomycetes as a source of new chemical diversity. 
The use of droplet-LMJ-SSP demonstrated the concentration of these secondary 
metabolites in guttates, suggesting that guttates may serve as a reservoir of secondary 
metabolites, at least under certain growth conditions.  
Experimental  
 General experimental procedures. The NMR data were collected using either a 
JEOL ECS-400 spectrometer (JEOL USA, Inc.) operating at 400 MHz for 1H and 100 
MHz for 13C, and equipped with JEOL normal geometry broadband Royal probe, or an 
Agilent 700 MHz NMR spectrometer (Agilent Technologies, Inc., Santa Clara, CA, 
USA) operating at 700 MHz for 1H and 175 MHz for 13C, and equipped with a cryoprobe. 
NMR chemical shift values were referenced to residual solvent signals for CD3OD (δH/δC 
3.31/49.0) and CDCl3 (δH/δC 7.26/77.2). HRESIMS data were obtained using a Thermo 
QExactive Plus mass spectrometer (ThermoFisher, San Jose, CA, USA) paired with an 
electrospray ionization source. Analysis of the fungal culture by in situ sampling was 
performed using the CTC/LEAP HTC PAL autosampler (LEAP Technologies Inc.) 
converted to an automated droplet-LMJ-SSP by using in-house developed software 
dropletProbe Premium. The droplet-LMJ-SSP was coupled with a Waters Acquity 
ultraperformance liquid chromatography (UPLC) system (Waters Corp.) and a Thermo 
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QExactive Plus. The HCD fragmentation used a normalized collision energy of 30 eV for 
all the compounds to obtain MS/MS data. The UPLC separation was performed using an 
Acquity BEH C18 column (50 mm x 2.1 mm i.d., 1.7 µm) equilibrated at 40 °C and a 
flow rate set at 0.3 mL/min. The mobile phase consisted of a linear CH3CN-H2O 
(acidified with 0.1% formic acid) gradient starting at 15% CH3CN to 100% CH3CN over 
8 min. The mobile phase was held for another 1.5 min at 100% CH3CN before going 
back to the starting conditions. The HPLC separations were performed using Varian 
ProStar HPLC system connected to a ProStar 335 photodiode array detector (PDA) with 
UV detection set at 210 nm and 254 nm. Preparative HPLC purification of isolated 
compounds was performed on a Phenomenex Synergi 4 µm particle size C18 column (21 
x 250 mm) at a flow rate of 21.24 mL/min. Flash column chromatography was carried 
out with a Teledyne ISCO Combiflash Rf connected to an ELSD and PDA detectors with 
UV detection set at 200-400 nm. The UV data were acquired using a Varian Cary 100 
Bio UV‒Vis spectrophotometer (Varian Inc., Walnut Creek, CA USA). The IR data 
were recorded using a Perkin-Elmer Spectrum One with Universal ATR attachment 
(PerkinElmer, Waltham, MA, USA). The melting point data were determined using an 
SRS DigiMelt Melting Point Apparatus, MPA 160 (Stanford Research Systems, Inc., 
Sunnyvale, CA, USA), and are uncorrected 
 Fungal strain isolation and identification. The fungal strain, G416, was isolated 
from partially decorticated submerged wood collected from Big Beaver Island creek in 
Madison, North Carolina, USA (36°27'40.0"N 80°01'46.0"W; water pH: 5; water temp 10 
°C). Sample collection and isolations were made using procedures outlined earlier.135  
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Identification of strain G416 was accomplished by analysis of molecular sequence data 
from the nuclear ribosomal internal transcribed spacer region (ITS rDNA). This gene 
region has been officially designated as the barcoding marker for species identification of 
fungal strains.136 In addition, portions of the 18S rDNA (partial SSU) and 28S rDNA 
(partial LSU) were also sequenced using primers NS1and NS4 for SSU 137 and LROR 
and LR6 for LSU.138,139 The DNA extraction, PCR amplification, sequencing protocols, 
and phylogenetic analysis were accomplished using methods described previously.120,126 
A BLAST search of the ITS sequence from G416 against GenBank suggested that the 
fungal strain had affinities with members of the frshwater ascomycetes genus 
Lindgomyces, (Lindgomycetaceae, Dothideomycetes, Ascomycota).120,133,140,141 Based on 
examination of morphology, and maximum likelihood analyses using portions of the 
rDNA gene (partial SSU, and partial LSU; Figure 70), the strain G416 has been identified 
as new species Lindgomyces madisonensis Raja & Oberlies.123 The Ex-holotype cultures 
(single ascospore isolate from holotype) of the newspecies have been deposited in the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany (DSMZ) as 
(DSM-100629) and Centraalbureau voor Schimmelcultures, Netherlands (CBS) as (CBS 
140367). A voucher culture of strain G416 is also maintained in the Department of 
Chemistry and Biochemistry culture collection at the University of North Carolina at 
Greensboro. The sequence data from the newly established species have been deposited 
in GenBank (SSU: KT207822, KT207823; ITS: KT207818, KT207819; and LSU: 
KT207820, KT207821). 
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Fermentation, Extraction, and Isolation. The fermentation for the fungal strain 
G416 was performed using procedures described previously with slight modifications.118 
Briefly, a seed culture of G416 was grown on a potato dextrose agar (PDA, Difco) slant 
for about 14 days. Subsequently, a small agar plug with mycelium was inoculated on 
liquid YESD media, followed by incubation for approximately 14 days at rt with shaking 
at 125 rpm using a rotary shaker. Once sufficient fu gal growth was observed in the seed 
culture, it was inoculated into four 250 mL Erlenmeyer flask, each containing 30 mL of 
autoclaved rice medium (consisting of 10 g of rice and deionized H2O that was twice the 
volume of rice) and grown at rt for a period of 28 days. 
 To each solid fermentation culture of G416, 60 mL of 1:1 CH3OH-CHCl3 was 
added, and these were shaken for 16 h on an orbital shaker. The resulting mixtures were 
filtered under vacuum, and the filtrate from each of the four Erlenmeyer flasks was 
combined. To the filtrate 360 mL of CHCl3 and 600 mL of H2O were added, and the 
mixture was stirred for 30 min and then transferred into a separatory funnel. The organic 
layer was drawn off and dried in vacuo. This dried organic extract was defatted by 
reconstituting in a mixture of 400 mL of 1:1 CH3OH-CH3CN and 400 mL of hexane, and 
then partitioned in a separatory funnel. The CH3O -CH3CN layer was collected and 
concentrated in vacuo. The resulting CH3OH-CH3CN extract (428 mg) was then adsorbed 
on Celite 545, and subjected to silica flash chromat gr phy on a 12 g RediSep Rf Gold 
Si-gel column, eluting with an increasing gradient of hexane to CHCl3 at a flow rate of 30 
mL/min over 61 column volumes, and for a duration of 34 min to give 48 fractions each 
containing 22 mL. The resulting fractions were then pooled according to their ELSD and 
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UV profiles, which resulted in five combined fractions in total. All were examined by 
analytical HPLC, and fractions 1-3 warranted furthe purification based on their 
chromatographic profiles. 
 Fraction 3 (23 mg) was purified further by preparative reversed phase HPLC 
eluting with a linear gradient from 40% to 60% CH3CN in H2O (0.1% formic acid) at a 
flow rate of 21.2 mL/min over 30 min to afford compound 1 (14.5 mg, tR =13.3 min). 
Fraction 2 (17 mg) was purified using the same preparative RP-HPLC conditions yielding 
compounds 2 (11.7 mg, tR =10.4 min) and 6 (1.4 mg, tR = 26.4 min). Fraction 1 (75 mg) 
was separated using a linear gradient from 40% to 80% CH3CN in H2O (0.1% formic 
acid) to give compounds 3 (1.4 mg, tR = 15.4 min), 4 (0.9 mg, tR = 13.2 min), 5 (8.1 mg, 
tR = 16.6 min), and 7 (0.9 mg, tR = 23.1 min). 
 madisone (1): White solid;m.p. 174-176 °C; UV (CH3OH) λmax (log ε) 306 
(3.30), 237 (3.25) nm; IR (ATR) νmax 3319, 3012, 2972, 2939, 2754, 1610, 1573, 1449, 
1265, 1195, 803 cm-1; 1H (400 MHz) and 13C NMR (100 MHz) both in CD3OD, see 
Table 19; HRESIMS m/z 227.09129 [M+H]+ (calc’d for C11H15O5, 227.09140).  
 4´-methoxymadisone (2): White solid; UV (CH3OH) λmax (log ε) 293 (3.33), 237 
(3.28) nm; IR (ATR) νmax 3275, 3007, 2976, 2940, 2885, 1618, 1579, 1416, 1265, 1122, 
866 cm-1; 1H (400 MHz) and 13C NMR (100 MHz) both in CD3OD, see Table 19; 
HRESIMS m/z 241.10681 [M+H]+ (calc’d for C12H17O5, 241.10705).  
 dehydromadisone (3): White solid; UV (CH3OH) λmax (log ε) 292 (3.27), 231 
(3.21) nm; 1H (400 MHz) and 13C NMR (100 MHz) both in CD3OD, see Table 19; 
HRESIMS m/z 211.09644 [M+H]+ (calc’d for C11H15O4, 211.09648). 
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 2´´-methoxymadisone (4): White solid; UV (CH3OH) λmax (log ε) 288 (2.92), 
226 (2.95) nm; 1H (700 MHz) and 13C NMR (175 MHz) both in CD3OD, see Table 20; 
HRESIMS m/z 241.10678 [M+H]+ (calc’d for C12H17O5, 241.10705). 
dihydroallovisnaginone (5): White solid; UV (CH3OH) λmax (log ε) 307 (3.26), 
241 (3.22) nm; IR (ATR) νmax 3106, 2986, 2950, 2908, 2864, 1628, 1594, 1389, 1286, 
1242, 1192, 884 cm-1; 1H (400 MHz) and 13C NMR (100 MHz) both in CD3OD, see 
Table 20; HRESIMS m/z 209.08083[M+H]+ (calc’d for C11H13O4, 209.08083).  
 dimadisone (6): White solid; UV (CH3OH) λmax (log ε) 292 (3.54), 235 (3.49) 
nm; 1H (400 MHz) and 13C NMR (100 MHz) both in CD3OD, see Table 20; HRESIMS 
m/z 435.16467 [M+H]+ (calc’d for C22H27O9, 435.16496).  
  4´-methoxydimadisone (7): White solid; UV (CH3OH) λmax (log ε) 292 (3.60), 
231 (3.54) nm; 1H (700 MHz) and 13C NMR (175 MHz) both in CD3OD, see Table 21; 
HRESIMS m/z 449.18039 [M+H]+ (calc’d for C23H29O9, 449.18061).  
 X-ray Crystallography. Crystals of compound 1 were grown in CH3OH at room 
temperature. A clear colourless irregular-shaped spcimen of C11H14O5, approximate 
dimensions 0.030 mm x 0.160 mm x 0.290 mm, was usedfor the X-ray crystallographic 
analysis. The X-ray intensity data were measured on a Bruker APEX CCD system 
equipped with a graphite monochromator and a Mo Kα sealed x-ray tube (λ = 0.71073 
Å). The total exposure time was 20.70 h. The frames w re integrated with the Bruker 
SAINT software package using a narrow-frame algorithm. The integration of the data 
using an orthorhombic unit cell yielded a total of 15607 reflections to a maximum θ angle 
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of 30.03° (0.71 Å resolution), of which 3150 were independent (Friedel opposites not 
merged, average redundancy 4.955, completeness = 99.7%, Rint = 4.04%, Rsig = 3.01%) 
and 2720 (86.35%) were greater than 2σ(F2). The final cell constants of a = 4.3710(4) Å, 
b = 11.6045(11) Å, c = 21.2672(19) Å, volume = 1078.74(17) Å3, are based upon the 
refinement of the XYZ-centroids of 4245 reflections above 20 σ (I) with 7.022° < 2θ < 
56.44°. Data were corrected for scaling and absorption effects using the multi-scan 
method (SADABS). The ratio of minimum to maximum app rent transmission was 
0.986. The calculated minimum and maximum transmission coefficients (based on crystal 
size) are 0.9690 and 0.9970. The structure was solved and refined using the Bruker 
SHELXTL Software Package, using the space group P212121, with Z = 4 for the formula 
unit, C11H14O5. The final anisotropic full-matrix least-squares rfinement on F2 with 159 
variables converged at R1 = 4.22%, for the observed data and wR2 = 10.90% for all data. 
The goodness-of-fit was 1.031. The largest peak in the final difference electron density 
synthesis was 0.318 e-/Å3 and the largest hole was -0.140 e-/Å3 with an RMS deviation of 
0.047 e-/Å3. On the basis of the final model, the calculated dnsity was 1.393 g/cm3 and F 
(000), 480 e-. Crystal data, data collection, and structure refinement details are 
summarized in Table 22-24. 
 Antimicrobial assay. Determination of the minimum inhibitory concentrations 
(MICs) of compounds 1, 2, and 5 against S. aureus, E. coli, M. smegmatis, C. albicans, 
and A. niger were performed according to previously described mthods.142,143 
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Figure 49. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Madisone (1) in CD3OD. 
X 
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Figure 50. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
4´-Methoxymadisone (2) in CD3OD. 
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Figure 51. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Dehydromadisone (3) in CD3OD. 
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Figure 52. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of  
2´´-Methoxymadisone (4) in CD3OD. 
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Figure 53. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Dihydroallovisnaginone (5) in CD3OD. 
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Figure 54. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 
Dimadisone (6) in CD3OD. 
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Figure 55. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 
4´-Methoxydimadisone (7) in CD3OD. 
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Figure 56. 1H NMR (400 MHz) Spectra of Compounds 1-7 in CDCl3. 
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Figure 57. The HMBC (400 MHz/100 MHz) Spectrum of Madisone (1) in CD3OD. 
 
 
  
 
Figure 58. The HMBC (400 MHz/100 MHz) Spectrum of 4́-Methoxymadisone (2) in 
CD3OD.  
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Figure 59. The HMBC (400 MHz/100 MHz) Spectrum of Dehydromadisone (3) in 
CD3OD.  
 
 
 
 
Figure 60. The HMBC (700 MHz/175 MHz) Spectrum of 2́́ -Methoxymadisone (4) 
in CD3OD. 
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Figure 61. The HMBC (400 MHz/100 MHz) Spectrum of Dihydroallovisnaginone (5) 
in CD3OD. 
 
 
 
 
Figure 62. The HMBC (400 MHz/100 MHz) Spectrum of Dimadisone (6) in CD3OD. 
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Figure 63. The HMBC (700 MHz/175 MHz) Spectrum of 4́-Methoxydimadisone (7) 
in CD3OD. 
 
 
 
 
Figure 64. Base Peak Chromatograms for G416 Sampled by the Droplet-LMJ-SSP. 
(A) Guttate Produced by G416 (B) Outer Mycelium of G416.  
(A) 
(B) 
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Figure 65. Data for the Reference Standard 1 (Top) and In Situ Analysis of G416 
Grown on PDA (Bottom). Overlay of chromatographic peaks of 1 (B) (+)-HRESIMS of 
1 (C) MS/MS HCD fragmentation of 1.  
 
 
 
 
Figure 66. Data for the Reference Standard 2 (Top) and In Situ Analysis of G416 
Grown on PDA (Bottom). (A) Overlay of chromatographic peaks of 2 and 4 (B) (+)-
HRESIMS of 2 and 4 (C) MS/MS HCD fragmentation of 2 and 4.  
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Figure 67. Data for the Reference Standard 3 (Top) and In Situ Analysis of G416 
Grown on PDA (Bottom). (A) Overlay of chromatographic peaks of 3 (B) (+)-
HRESIMS of 3 (C) MS/MS HCD fragmentation of 3.  The top and bottom show the data 
for the reference standard and i  situ analysis of G416 grown on PDA, respectively. 
 
 
 
 
Figure 68. Data for the Reference Standard 5 (Top) and In Situ Analysis of G416 
Grown on PDA (Bottom). (A) Overlay of chromatographic peaks of 5 (B) (+)-
HRESIMS of 5 (C) MS/MS HCD fragmentation of 5.  
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Figure 69. Data for the Reference Standard 6 (Top) and In Situ Analysis of G416 
Grown on PDA (Bottom). (A) Overlay of chromatographic peaks of 6 (B) (+)-
HRESIMS of 6 (C) MS/MS HCD fragmentation of 6.  
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Figure 70.  Phylogram of The Most Likely Tree (-lnL = 10047.29) From a RAxML 
Analysis of 70 Taxa Based on Combined SSU and LSU nrDNA Sequence Data (2309 
bp). Numbers refer to RAxML bootstrap support values ≥ 70 % based on 1000 replicates 
and significant Bayesian posterior probabilities ≥ 95 %. New species of strain G416 is 
indicated in bold and is identified as having phylogenetic affinities to members of the 
freshwater ascomycete genus Lindgomyces. Bar indicates nucleotide substitutions per 
site.   
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Figure 71. The Molecular Structure of 1 Depicted with 50% Probability 
Displacement Ellipsoids. 
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Table 22. Crystal Data for Compound 1. 
 C11H14O5 Dx = 1.393 Mg m-3 
Mr = 226.22 Mo Kα radiation, λ = 0.71073 Å 
Orthorhombic, P212121 Cell parameters from 4245 reflections 
a = 4.3710 (4) Å θ = 3.5–28.2° 
b = 11.6045 (11) Å µ = 0.11 mm-1 
c = 21.2672 (19) Å T = 193 K 
V = 1078.74 (17)  Å3 Irregular, colourless 
Z = 4 0.29 × 0.16 × 0.03 mm 
F(000) = 480  
 
 
Table 23. Crystal Data Collection Parameters for Compound 1. 
 Bruker APEX CCD  
diffractometer 
3150 independent reflections 
Radiation source: sealed tube 2720 reflections withI > 2σ(I) 
Graphite monochromator Rint = 0.040 
φ and ω scans θmax = 30.0°, θmin = 3.5° 
Absorption correction: multi-scan  
data were corrected for scaling and absorption 
effects using the multi-scan technique 
(SADABS). The ratio of minimum to maximum 
apparent transmission was 0.986. The   
calculated minimum and maximum 
transmission  coefficients (based on crystal 
size) are 0.969 and 0.997. 
h = -6→6 
Tmin = 0.735, Tmax = 0.986 k = -16→16 
15607 measured reflections l = -29→29 
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Table 24. Refinement Details for Crystal Data Collection for Compound 1. 
 
 Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site locati n: difference 
Fourier map 
R[F2 > 2 σ(F2)] = 0.042 Hydrogen site location: mixed 
wR(F2) = 0.109 H atoms treated by a mixture of independent 
and constrained refinement 
S = 1.03  w = 1/[σ2(Fo2) + (0.0583P)2 + 0.116P]   
where P = (Fo2 + 2Fc2)/3 
3150 reflections (∆/ σ)max = 0.001 
159 parameters ∆〉max = 0.32 e Å-3 
0 restraints ∆〉min = -0.14 e Å-3 
Special details 
Geometry. All esds (except the esd in the dihedral angle betwe n two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by 
crystal symmetry.  An approximate (isotropic) treatment of cell esds is used for 
estimating esds involving l.s. planes. 
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Table 25. Antimicrobial Activities of Compounds 1, 2, and 5. 
Compound 
Minimum inhibitory concentration (µg/mL) 
S. aureus E. coli M. smegmatis C. albicans A. niger 
1 >55 >55 >55 >55 >55 
2 >55 >55 >55 >55 >55 
5 >55 >55 >55 >55 >55 
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CHAPTER IV 
PRENYLATED XANTHENES AS QUORUM SENSING INHIBITORS FROM A 
FRESHWATER LEOTIOMYCETES SP. 
 
This chapter is intended for publication to Journal of Natural Products (2017) and 
is presented in that style. Coauthors include José Rivera-Chávez, Justin Stempin, 
Mario Augustinovic, Aleksandra I. Noras, Huzefa A. Raja, Daniel A. Todd, 
Kathleen Triplett, Cynthia Day, Mario Figueroa, Pamela R. Hall, Nadja B. Cech 
and Nicholas H. Oberlies. 
 
 
Freshwater fungi are an underexplored ecological group with a high potential for 
discovery of new bioactive secondary metabolites. In the course of our investigation of 
freshwater fungi from North Carolina, we investigated an isolate of Leotiomycetes sp. 
which led to the isolation of three new prenylated xanthenes (1-3) along with two known 
compounds 4R-regiolone (4), and decarboxycitrinone (5). Their structures were assigned 
on the basis of HRESIMS and NMR experiments. The structure of compound 1 was 
confirmed via x-ray diffraction analysis, and its absolute configuration was established by 
TDDFT-ECD calculations. Compounds 1-3 suppressed quorum sensing in a clinical 
isolate of methicillin-resistant Staphylococcus aureus (MRSA), with IC50 values ranging 
from 0.3 to 12.5 µM suggesting potential antivirulence activity for the compounds.  
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections 
is a major public health burden, exacerbated by the em rgence of community-associated 
(CA) MRSA, which causes significant morbidity and mortality worldwide.144,145 In the
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 US, the Centers for Disease Control and Prevention estimated that there are at least 
80,000 incidences of severe MRSA infections per yea, with about 11,000 cases leading 
to death.146 Addressing this urgent health threat an executive ord r was issued by the 
White House in 2014, launching an interagency task force charged with developing a 
five-year national action plan to combat the emergence and spread of antibiotic-resistant 
bacteria.147 Part of the strategy depends on the acceleration of research on the 
development of new antibacterial drugs and other novel therapeutics.147 In 2017, the 
World Health Organization listed MRSA as one of the priority pathogens that cause the 
greatest threat to human health, and they called for the development of new antibiotics 
and better treatment options to reduce the severity of the impact of these pathogens.148  
Several alternative approaches have been explored f combating bacterial 
infections, and one of these is focused on blocking bacterial pathogenesis without killing 
or inhibiting bacterial growth.149-155 By controlling bacterial virulence, it has been 
proposed that selective pressure toward resistance dev lopment would be prevented or 
minimized, thereby decreasing antibiotic use and, i theory, decreasing the occurrence of 
infections with drug-resistant pathogens.149,150 In Staphylococcus aureus the expression 
of virulence factors is mediated by the accessory gene regulator (agr) quorum sensing 
system,156 which regulates the secretion of the virulence factors that lead to 
pathogenicity. Therefore, disrupting the agr system is a promising target to combat S. 
aureus infections.157 
Natural products continue to be a prolific source of therapeutics as a large extent 
of the world’s biodiversity has been untapped for chemical diversity and biological 
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activity.1,158 Current studies have identified a few small molecul s with anti-virulence 
activity against S. aureus, including ambuic acid159 and ω-hydroxyemodin,160,161 both of 
which are fungal secondary metabolites. It is known that bacteria and fungi in their 
natural environment can interact with each other via chemical communication.162 These 
interactions often result in changes in the production of small molecules that either affect 
the pathogenicity of one or both organisms. This concept led us to hypothesize that fungi 
inherently have the ability to produce compounds that can modulate bacterial quorum 
sensing. Thus we predicted that fungal metabolites could play a significant role in the 
discovery of antivirulence agents. 
Freshwater ascomycetes are an ecological group of fungi with about 1500 
described species to date.163,164 These fungi are adapted to lentic and lotic habitats, 
primarily as parasites and endophytes of aquatic macrophytes and algae, and as organic 
matter decomposers.39,163-165 Our earlier studies of the freshwater ascomycetes from
North Carolina have been productive from both mycological and chemical 
perspectives,122,166-171 but far from exhaustive, representing only a minor fraction of the 
immense potential of these organisms. As part of our ongoing studies to further explore 
the chemical diversity of these organisms and identfy fungal natural products that target 
virulence in MRSA, we investigated an isolate identified as Leotiomycetes p. 
(accessioned as G730). The fungal isolate (G730) was collected from submerged wood in 
a freshwater lake in Hanging Rock State Park, North Carolina. Investigation of the 
secondary metabolites from Leotiomycetes sp. led to the isolation of three new 
prenylated xanthenes 1-3 and two known compounds (4-5). The structures of these 
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metabolites were assigned by NMR and HRESIMS. The structural assignments of 1 
based on NMR data were confirmed by X-ray crystal diffraction analysis. The absolute 
configuration of 1 was determined using ECD spectroscopy combined with time-
dependent density functional theory and quantum chemical ECD calculations (TDDFT-
ECD). The new prenylated xanthenes (1-3) were tested for antivirulence against MRSA 
strain USA300 LAC strain (AH1263)172 and showed promising results. 
Results and Discussion 
An organic extract from G730 showed promising antivirulence activity when 
tested in a quorum sensing inhibition assay against  clinical isolate of a USA300 LAC 
strain of MRSA (AH1263)172. Conventional bioassay guided fractionation of the extract 
using chromatographic procedures led to the isolation of three new prenylated xanthenes 
(1-3) which were ascribed the trivial names Leotiomyxene A-C, respectively.  Moreover, 
the known compounds 4R-regiolone (4),173 and decarboxycitrinone (5)174 were also 
isolated and identified based on NMR, HRMS, and optical rotation data, which were in 
agreement to the literature. 
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Figure 72. Structures of Compounds 1-5 Isolated and Identified From an Organic 
Extract of G730. 
 
 
Leotiomycene A (1) was obtained as whitish yellow, amorphous powder. The 
molecular formula for 1 was established as C20H20O5 based on HRESIMS data ([M+H]+ 
ion at m/z 341.1380, calcd 341.1384) and NMR data, indicating an index of hydrogen 
deficiency of eleven. Analysis of the 1H and 13C NMR data indicated the presence of 20 
carbon atoms, consisting of four methyl groups, five methines (three aromatic, one 
olefinic, and one aliphatic), and eleven non-protona ed carbons (nine aromatic, one 
olefinic, and one carbonyl). Based on 1D and 2D NMR data (Table 26, Figures 78-81) 
three partial structures of 1 were elucidated (Figure 73). 
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Figure 73. Partial Structures, Selected HMBC and NOESY 
Correlations of Compound 1. 
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Table 26. 1H (400 Mhz) and 13C (100 MHz) NMR Data for Compound 1 in CDCl3. 
 1 
position δC Type δH, mult 
(J in Hz) 
HMBC 
1 164.1 C   
2 105.4 C   
3 142.6 C   
4 111.8 CH 6.48, s 2, 4a, 9a, 11, 12 
4a 155.9 C   
5 109.8 CH 6.52, bs 5a, 7, 8, 8a, 13  
5a 150.7 C   
6 138.6 C   
7 112.3 CH 6.45, bs 5, 8, 8a, 13 
8 154.3 C   
8a 108.5 C   
9 28.3 CH 4.96, d 
(10.4) 
1, 4a, 5a, 1´, 2´ 
9a 109.1 C   
11 175.4 C   
12 24.4 CH3 2.58, s 1, 2, 3, 4, 11 
13 21.4 CH3 2.28, s 5, 6, 7 
1´ 125.4 CH 5.01, dm 
(10.4) 
3´, 4´ 
2´ 132.6 C   
3´ 18.2 CH3 2.04, s 1´, 2´, 4´ 
4´ 25.9 CH3 1.69, s 1´, 2´, 3´ 
1-OH   11.90, s 1, 2, 4a, 9a 
8-OH     
 
 
Resonances for a pentasubstituted and 1,2,3,5-tetrasubstituted aromatic rings were 
identified based on the singlet resonance at δH 6.48 (H-4) and signals for meta-coupled 
protons at δH 6.52 (H-5) and δH 6.45 (H-7) (both observed as broad singlets). 
Furthermore, the 13C NMR shifts (δC 164.1, 155.9, 150.7, 154.3) observed for the 
aromatic moieties C-1, C-4a, C-5a, and C-8, respectively indicated that they are both 
dioxygenated.  HMBC correlations from H-4 to C-4a/C-9a; H3-12 to C-2/C-4/C-11/ C-
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12, in combination with the NOESY cross-peaks betwen H-4 and H3-12, and the 
presence of a phenolic hydroxy resonance at δH 11.90 (1-OH) chelated with the 
carboxylic acid moiety at δC 175.4 (C-11) allowed the assembly of ring A. Similarly, ring 
B was assigned based on the HMBC from H-5 to C-5a/C-8a/ -13 and from H-7 to C-
8/C-8a/ C-13, and the NOESY cross peaks observed between H3-13 and H-5, and H3-13 
and H-7. The remaining fragment in 1 was elucidated as a prenyl moiety based on HMBC  
and 1H-1H COSY experiments. This prenyl moiety was attached to C-8a of ring A and C-
9a of ring B as supported by HMBC correlations observed from H-9 to C-1/C-4a/C-5a/C-
8/C-8a/C-9. Consideration of the molecular formula and the unsaturation requirement of 
1, along with the downfield shifts of C-4a (δC 155.9) and C-5a (δC 150.7) indicated the 
ether linkage between rings A and B at C-4a and C-5a forming ring C which established 
the 9H-xanthene skeleton. Altogether, these correlations resulted in the planar structure 
of the new metabolite 1. During the course of this study, crystals were obtained from a 
concentrated 1:1 acetone-hexane solution of 1. X-ray diffraction analysis of a suitable 
crystal confirmed the proposed structural assignments of 1 as shown in Figure 74.  
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In order to determine the absolute configuration of 1 at C-9, the experimental 
ECD of 1 and the time-dependent density functional theory-calculated (TDDFT) ECD 
spectra for enantiomer 9R and 9S of 1 were compared. In brief, TDDFT calculations were 
performed by minimization of the structure of each enantiomer, followed by a 
conformational search using a Monte Carlo protocol. C nformers for each enantiomer 
that were within a 10 kcal/mol window were selected an  reoptimized using DFT 
calculations at the B3LYP/6-311+G (2d,p) level of theory. Finally, the theoretical ECD 
spectra of each conformer of the 9R and 9S enantiomers were calculated using TDDFT at 
the same level of theory with the polarizable continuum model in CH3CN. The specific 
optical rotation values for enantiomers 9R and 9S were also calculated. The calculated 
ECD spectrum based on TDDFT for the 9S enantiomer  matched well with the 
experimentally measured data, which displayed a positive and a negative Cotton effect at 
~210 and ~230, respectively (Figure 75). Furthermore, the calculated specific optical 
rotation value for the 9S enantiomer ([α]25D +117) was in agreement with the 
 
 
Figure 74. ORTEP Drawing of Two Molecules of Compound 1 
Showing Intra- and Intermolecular H-bonding Indicated by Green 
Dashed Lines. 
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experimental data ([α]25D +90 ). Thus, the absolute configuration of 1 at C-9 was assigned 
as S.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A molecular formula consisting of C20H22O5 (ten unsaturations) was assigned for 
leotiomycene B (2) based on HRESIMS data ([M+H]+ ion at m/z 343.1530, calcd 
343.1540) and NMR data (Table 27, Figure 82-84). The 1H NMR spectrum of 2 
displayed signals similar to those of 1, with notable differences consisting of an 
additional aromatic proton signal H-9a (δH 6.20, d, J = 2.4 Hz), and an upfield shifted 
signal for methylene protons H2-9 (δH 3.24, d, J = 7.1 Hz) in contrast to a methine (δH 
4.96, d, J=10.4 Hz) in 1 in the prenyl portion of the molecule. Considering these changes 
in the 1H NMR spectrum and a decrease of an unsaturation cou t in 2 relative to 1, a loss 
 
Figure 75. Comparison of the Experimental and Calculated 
(at the B3LYP/6-311+G(2d,p) Level) ECD Spectra of 1in 
MeCN. 
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of the 9H-xanthene skeleton was proposed for 2. This was later confirmed on the basis of 
the meta-coupling observed (J= 2.4 Hz) between H-9a and H-4 (δH 6.37, d) and the 
HMBC correlations from H-9a to C-1/C-2/C-4/C-4a, and from H-9 to C-5a/C-8/C-8a. 
Overall, the detected HMBC correlations for 2 were almost identical to 1. The main 
difference was the lack of cross peaks from H2-9 to C-9a, suggesting 2 to be the seco 
derivative of 1. Thus, the structure of 2 was established as illustrated.  
 
Table 27. 1H (400 MHz) and 13C (100 MHz) NMR Data for Compound 2 in CDCl3. 
 2 
position δC Type δH, mult 
(J in Hz) 
HMBC 
1 166.3 C   
2 105.0 C   
3 145.3 C   
4 112.5 CH 6.37, d (2.4) 2, 4a, 9a
4a 164.2 C   
5 114.7 CH 6.43, bs 5a, 7, 8a, 13 
5a 152.3 C   
6 138.4 C   
7 114.1 CH 6.56, bs 5, 8, 8a, 13
8 156.0 C   
8a 117.0 C   
9 23.1 CH2 3.24, d (7.1) 5a, 8, 8a, 1´, 2´
9a 102.0 CH 6.20, d (2.4) 1, 2, 4, 4a 
11 175.0 C   
12 24.6 CH3 2.57, s 2, 3, 4, 11 
13 21.3 CH3 2.26, s 5, 6, 7 
1´ 121.3 CH 5.16, tm 
(7.1) 
3´, 4´, 9 
2´ 135.3 C   
3´ 18.0 CH3 1.71, bs 1´, 2´, 4´ 
4´ 25.9 CH3 1.69, bs 1´, 2´, 3´ 
1-OH   11.44, s 1, 2, 4a, 9a 
8-OH   5.26 bs  
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Table 28. 1H (500 MHz) and 13C (125 MHz) NMR Data for Compound 3 in CDCl3 
position δC Type δH, mult  
(J in Hz) 
HMBC 
1/8 154.3 C   
2/7 111.2 CH 6.36, bs 1, 4, 9a, 11/5, 8, 8a, 12 
3/6 138.6 C   
4/5 109.8 CH 6.49, bs 2, 4a, 9a,11/7, 5a, 8a, 12 
4a/5a 151.6 C   
8a/9a 107.5 C   
9 28.7 CH 4.91, d (10.4) 1/8, 4a/5a, 8a/9a, 1´, 2 
11/12 21.3 CH3 2.26, s 2, 3, 4/5, 6, 7 
1´ 126.4 CH 5.16, dm 
(10.4) 
3´, 4  ́
2´ 132.2 C   
3´ 18.0 CH3 2.05, d (1.4) 1´, 2´, 4´ 
4´ 25.9 CH3 1.73, d (1.1) 1´, 2´, 3´ 
1-OH/8-OH   4.88, s 1, 2, 9a/7, 8, 8a
 
 
Leotiomycene C (3) was isolated as an optically inactive white powder. Its 
molecular formula, C19H20O3, established from HRESIMS data ([M+H]+ ion at m/z 
297.1480, calcd 297.1485) and NMR data (Table 28, Figure 85-87), indicated a structure 
with ten degrees of unsaturation. These data were consistent with compound 3 being a 
decarboxylated analogue of 1. The 1H NMR spectrum of 3 displayed only one set of 
signals for the meta-coupled protons H-2/7 and H-4/5 (broad singlets δH 6.36 and δH 6.49, 
respectively)  in rings A and B, as well as the methyl H3-11/12 (δH 2.26, s) and hydroxyl 
1-OH/8-OH (δH 4.88, s) groups. Likewise, the 13C NMR spectrum only displayed one set 
of signals for the aromatic carbons C-1/8, C-2/7, C-3/6, C-4/5 (δC 154.3, 111.2, 138.6, 
109.8, respectively) in both rings. Based on these data, along with the analysis of the 2D 
NMR data, it was concluded that decarboxylation at C-2 rendered the two halves of the 
molecule symmetrical. This therefore indicated thatcompound 3 do not have a chiral 
122 
 
center at C-9 which was supported by the lack of optical activity observed for the 
compound. Altogether, the structure of 3 was assigned as shown. 
Compounds 1-3 were evaluated as quorum sensing inhibitors against AH1263 at 
below growth-inhibitory concentrations. As shown in Table 29, 1-3 suppressed quorum 
sensing with IC50 values in the 0.3-12.5 µM range. The most potent activity was detected 
for compound 1 with an IC50 of 0.3 ± 0.1 µM. The results also indicated that 1 was more 
potent than the positive controls ambuic acid and ω-hydroxyemodin. 
 
Table 29. Activity of Compounds 1-3 as Agr Quorum Sensing Inhibitors 
Compound IC50 (µM) 
1 0.3 ± 0.1 
2 4.6 ± 2.3 
3 6.3-12.5 
*ambuic acid 1.3 ± 0.1 
*ω-hydroxyemodin 6.3-12.5 
  *Positive control 
 
 
To support the antivirulence activity observed mainly for compound 1, it was 
evaluated for the suppression of the transcription of the agr effector RNAIII and agr-
regulated virulence factors, including phenol soluble modulin alpha (psmα) and alpha-
hemolysin (hla) in the same MRSA strain (AH1263). RNAIII is the intracellular effector 
of the quorum sensing system in S. aureus that controls the expression of  >200 virulence 
factors that lead to invasive infections.161 Based on the results (Figure 76), compound 1 
decreased the transcription of RNAIII at 9.0 and 16.0 µM concentrations. As anticipated 
based on the inhibition of RNAIII transcription, compound 1 suppressed the production 
of both psmα and hla (Figure 76) at 2.9, 9.0 and 16.0 µM concentrations. These results 
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indicated that compound 1 was inhibiting S. aureus quorum sensing-mediated 
pathogenesis by disrupting part of the agr system that modulates production of virulence 
factors that target adaptive immunity during invasie infections. 
 
 
Figure 76. Relative Quantification of (A) RNAIII, (B) Psmα, and (C) Hla by 
qRT-PCR Relative to 16S rRNA Following a 5 h Incubation of USA300 LAC 
(2 x 107 CFU/mL) and Compound 1 or Vehicle. Data are represented as the fold 
change relative to 16S rRNA as compared to inoculum bacteria. Data are 
represented as the mean ± SEM, n = 3 replicates of a representative experiment of 
two independent experiments. ** p<0.01 based on Mann Whitney U test. 
 
 
Due to structural similarities of 1 to a fragment compound (9H-xanthene-9-
carboxylic acid) identified previously as an inhibitor of AgrA (cytoplasmic response 
regulator protein of the agr quorum sensing system),176 we hypothesized that 1 would be 
an inhibitor of the same component of the agr quorum sensing system. To predict the 
mode of inhibition for 1, the potential binding sites on the crystal structure of the C-
terminal AgrA DNA binding domain (PDB ID 4G4K) were evaluated via in silico 
docking calculations (Figure 77A). The compound waspredicted to dock in a pocket 
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(binding energy (∆G) = -5.5 kcal/mol) between the side chains of Thr142, Lys146, 
Phe182, Asn185, Leu189, and Leu192, and formed hydrogen bonds between Glu144 and 
Leu145 (Figure 77A-B).  
The polyhydroxyanthraquinone ω-hydroxyemodin is a fungal secondary 
metabolite that has been recently shown to have in ivo efficacy against quorum sensing 
in S. aureus.161 Comparison of the putative mode of binding of 1 and ω-hydroxyemodin 
on AgrAC indicated that these compounds have the same potential bi ding sites on the 
protein structure (Figure 77C).  The calculated binding energy for the best docking pose 
for ω-hydroxyemodin was -5.95 kcal/mol. The compound wasobserved to bind in a 
pocket bounded by the side chains of Thr142, Tyr156, Lys146, Gly184, Leu189, Leu192, 
and had hydrogen bond interactions with Ile143, Glu144,  Asn185, and Glu188. 
 
 
Figure 77.  Compound 1 In Silico Binding Predictions on AgrA. (A) The putative 
mode of binding for compound 1 on AgrAc crystal structure (PDB ID 4G4K) as predicted 
by in silico docking calculations. (B) Optimized view of the binding mode for 1. 
Predicted hydrogen bonds between 1 and the amino acids (Leu145 and Glu144) are 
indicated by green dashed lines. (C) The known AgrA inhibitor ω-hydroxyemodin 
(yellow) and compound 1 bound to the same pocket on AgrA. 
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The similarities in the predicted binding pockets on AgrAC for 1 and ω-
hydroxyemodin indicated that the two c mpounds could potentially have the same mode 
of action in suppressing quorum sensing in MRSA. To address this possibility, it will be 
important to experimentally characterize the mechanisms of action of 1 with more 
confirmatory assays.161 Overall, the isolation and characterization of the new prenylated 
xanthenes 1-3 from Leotiomycetes p. highlighted the importance of freshwater fungi as 
a potential source for new drug leads. The identification of the antivirulence activity of 1-
3 could possibly contribute to the promotion of antibiotic stewardship. 
Experimental Section 
General experimental procedures. All solvents and chemicals were purchased 
from standard suppliers and were used without any further purification. The NMR data 
were collected using either a JEOL ECS-400 spectrometer (JEOL USA, Inc.) operating at 
400 MHz for 1H and 100 MHz for 13C, and equipped with JEOL normal geometry 
broadband Royal probe; or a JEOL ECA-500 spectrometer (JEOL USA, Inc.) operating 
at 500 MHz for 1H and 125 MHz for 13C; or an Agilent 700 MHz NMR spectrometer 
(Agilent Technologies, Inc., Santa Clara, CA, USA) operating at 700 MHz for 1H and 
175 MHz for 13C, and equipped with a cryoprobe. NMR chemical shift values were 
referenced to residual solvent signals for CDCl3 (δH/δC 7.26/77.2). HRESIMS data were 
obtained using a Thermo QExactive Plus mass spectrome er (ThermoFisher, San Jose, 
CA, USA) with an electrospray ionization source coupled with a Waters Acquity 
ultraperformance liquid chromatography (UPLC) system (Waters Corp.). The UPLC 
separation was performed using an Acquity BEH C18 column (50 mm x 2.1 mm i.d., 1.7 
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µm) equilibrated at 40 °C and a flow rate set at 0.3 mL/min. The mobile phase consisted 
of a linear CH3CN-H2O (acidified with 0.1% HCOOH) gradient starting at 15% CH3CN 
to 100% CH3CN over 8 min. The mobile phase was held for another 1.5 min at 100% 
CH3CN before going back to the starting conditions. The HPLC separations were 
performed using Varian ProStar HPLC system connected to a ProStar 335 photodiode 
array detector (PDA) with UV detection set at 210 nm and 254 nm. Preparative reversed 
phase HPLC purification of samples was performed on an Atlantis® Prep T3 (5 µm; 
250 × 19 mm) column using a 17 mL/min flow rate of the mobile phase consisting of a 
mixture of CH3CN and H2O (with 0.1% HCOOH). Flash column chromatography was 
carried out with a Teledyne ISCO Combiflash Rf connected to an evaporative light 
scattering detector and PDA detectors with UV detection set at 200-400 nm. Optical 
rotation data were acquired on a Rudolph Research Autopol III polarimeter (Rudolph 
Research Analytical, Flanders, NJ, USA). The UV data were acquired using a Varian 
Cary 100 Bio UV‒Vis spectrophotometer (Varian Inc., Walnut Creek, CA USA). The 
ECD data were collected with an Olis DSM 17 ECD spectrophotometer (Olis, Inc., 
Bogard, GA, USA).  
Fungal strain isolation and identification. The fungal strain, G730 was isolated 
serendipitously from a sample of submerged wood colle ted in March of 2015 from a 
freshwater lake in Hanging Rock State Park, North Carolina (N 36 23.433, W 80 16.64), 
while attempting to isolate a new genus of freshwater scomycetes (data not shown). The 
single spore isolation of the new fungal genus failed as it was contaminated by hyphal 
growth from strain G730, which was subsequently purified and isolated using antibiotic 
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water agar (AWA; agar 20 g, streptomycin sulfate 250 mg/L, penicillin G 250 mg/L, 
distilled water 1L; antibiotics were added to the molten agar immediately after 
autoclaving). A culture of strain G730 is preserved in the Department of Chemistry and 
Biochemistry culture collection at the University of North Carolina at Greensboro. For 
isolation of freshwater fungi, previously outlined collection and isolation methods by 
Shearer et al.177 were implemented. Morphological examination of fungal cultures grown 
on different nutrient media types, such as Potato Dextrose Agar (PDA; Difco), Potato 
Carrot Agar (PCA; Himedia) indicated that the strain G730 grew only as sterile mycelia. 
Fruiting body formation was induced by adding a piece of sterilized balsa to the nutrient 
media177; however, after two/three months no ascoma were obs rved on the balsa wood 
or the PDA plates. Since no morphological data were available for identification of 
fungal strain G730, molecular sequencing was performed. Molecular data for strain G730 
were obtained by sequencing the internal transcribed spacer regions 1 and 2 and 5.8S 
nrDNA (ITS)178 along with the D1 and D2 regions of the 28S nuclear ribosomal large 
subunit rRNA gene (LSU).139,179 The ITS region was used for DNA barcoding180, while 
the LSU region was utilized for phylogenetic analysis.96 DNA extraction, PCR 
amplification, and sequencing were performed according to previously published 
procedures.96 A BLAST search in GenBank using the complete ITS rDNA sequence 
showed low homology (81% similarity) with members of Leotiomycetes sp. genotype 
727 JMUR-2016 voucher ARIZ: FL1722 (KX908942), Leotiomycetes sp. genotype 730 
JMUR-2016 voucher ARIZ: FL1746 (KX908694), and Phialocephala 
fortinii (LC131022). To better predict the phylogenetic affiliations of G730 to taxa within 
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the Leotiomycetes, Ascomycota, a molecular phylogenetic analysis using maximum 
likelihood was undertaken using LSU data for strain G730, along with sequences of the 
diverse aquatic and terrestrial Helotialean taxa of the Leotiomycetes from previous 
molecular phylogenetic studies.181-185 Maximum Likelihood analysis was implemented 
using RAxML v. 7.0.4186 run on the CIPRES portal187 with the default rapid hill-climbing 
algorithm and GTR model employing 1000 fast bootstrap searches. Clades with bootstrap 
values ≥70% were considered to be significant and strongly supported.188 In addition, 
Bayesian analysis using Markov Chain Monte Carlo (MCMC) algorithm was performed 
using Mr. Bayes189,190 as an additional measure of branch support assessment using the 
GTR+I+G model of evolution191. Detailed methodology of the phylogenetic analysis ha  
been outlined previously.96 Results of the phylogenetic analysis indicated that str in 
G730 has phylogenetic affinities to the Vibrissea-Loramyces Clade sensu Wang et al182; 
G730 was nested within a clade containing genera such as, Vibrissea, Loramyces, 
Mollisia, Strossmayeria, with moderate RAxML bootstrap support (69%), but without 
Bayesian posterior probability support (Figure 90). On the basis of these data, G730 is 
tentatively identified as Leotiomycetes sp., Ascomycota. A number of freshwater fungi 
belonging to the Leotiomycetes have been isolated from submerged wood previously.192 
Based on the distant homology to ribosomal sequences present in NCBI GenBank, it is 
likely that strain G730 may represent a new genus ad/or species; however, since G730 
only occurs only as sterile mycelia, it is conservatively referred to as Leotiomycetes sp. 
The complete ITS and combined ITS-LSU sequences were d posited in GenBank 
(accession no. ITS: XXXX; ITS-LSU:XXXX, XXXX ). 
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 Fermentation, extraction, and isolation. A fresh culture of G730 was grown on 
potato dextrose agar and maintained at rt. Once good rowth was observed, a culture plug 
was subsequently inoculated into a 15 mL liquid medium consisting of 2% soy peptone, 
2% dextrose, and 1% yeast extract (YESD). This was followed by incubation with 
agitation at rt for about 7 days using a rotary shaker. Once sufficient fungal growth was 
observed the seed culture was used to inoculate a 250 mL Erlenmeyer flask containing an 
autoclaved rice medium (10 g rice added with 25 mL deionized H2O). The fermentation 
culture was allowed to grow at rt for a period of 30 days. Six fermentation cultures of 
G730 were prepared, each was extracted by addition of 1:1 CH3OH-CHCl3 (60 mL) with 
overnight shaking, filtered, and then all the filtrates were combined.  
To the combined filtrate, 500 mL of CHCl3 and 900 mL of H2O were added, 
stirred for 0.5 h, partitioned, the CHCl3-soluble layer collected and dried in vacuo. The 
resulting extract was further partitioned between CH3OH-CH3CN (1:1, 300 mL) and 
hexanes (300 mL) to remove lipids, and then the CH3OH-CH3CN soluble layer was 
dried in vacuo. The dried material (1.2 g) was adsorbed on Celite 545, and subjected to 
silica flash chromatography on a 24 g RediSep Rf Gold Si-gel column, eluting with use 
of a gradient solvent system of hexane-CHCl3- H3OH at a flow rate of 35 mL/min over 
41 column volumes, and for a duration of 40 min to give 100 fractions each containing 
15 mL. The fractions were then pooled according to their ELSD and UV profiles, which 
resulted into six fractions.  
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 Fraction 2 (556 mg) was subjected to preparative re rsed-phase HPLC eluting 
with a linear gradient from 50% to 60% CH3CN in H2O (0.1% HCOOH) over 30 min to 
afford 11 fractions, with the ninth and seventh fraction being compounds 1 (190 mg) and 
2 (7.0 mg), respectively.  Fraction eight (142 mg) was repurified using an isocratic 
condition consisting of 50% CH3CN in H2O (0.1% HCOOH) over 60 min to afford 
compound 3 (0.9 mg) and more of compounds 1 (115 mg) and 2 (2.4 mg). 
Leotiomycene A (1): white solid; [α]27D +90 (c 0.1, MeCN); UV (MeCN) λmax 
(log ε) 215 (4.5), 291 (4.1) nm; 1H and 13C NMR, see Table 26; HRESIMS m/z 341.1379 
[M+H] + (calcd for C20H21O5, 341.1384 ). 
Leotiomycene B (2): white solid; UV (MeCN) λmax (log ε) 210 (4.8), 265 (4.2), 
307 (3.9) nm; 1H and 13C NMR, see Table 27; HRESIMS m/z 343.1530 [M+H] + (calcd 
for C20H23O5, 343.1540 ). 
Leotiomycene C (3): white solid; UV (MeCN) λmax (log ε) 221 (4.3), 282 (3.3) 
nm; 1H and 13C NMR, see Table 28; HRESIMS m/z 297.1480 [M+H]+ (calcd for 
C19H21O3, 297.1485). 
 The agr quorum sensing system inhibition assay. A Synergy H1 Multi-Mode 
Reader (Biotek Instruments, Inc., Winooski, VT) was used to obtain optical density (OD600) 
readings. Liquid chromatography-mass spectrometry (LC-MS) wasperformed using an 
Aquity ultra-high performance liquid chromatography (UPLC) system (Waters Corporation, 
Milford, MA) coupled to a QExactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA). The positive control ambuic acid was purchased 
from Adipogen International, San Diego, CA. 
131 
 
Mass spectrometric measurements to evaluate AIP producti n inhibition was 
performed according to a method described previously.175 Briefly, the bacteria were 
cultured in the presence of the test substance in triplicate wells in a 96 well plate format. 
The bacterial cell growth was monitored at 1 h interval by measurement of OD600 to 
determine growth inhibition or delay. At the end of log-phase growth, the cells were 
filtered and the filtrate analyzed using a UPLC coupled to MS.  IC50 values were 
determined from a four parameter logistic function in Sigmaplot. 
 Quantitative PCR for S. aureus gene transcription. For the quantification of S. 
aureus gene transcription, 500-µl cultures at 2 × 107 CFU/mL of USA300 LAC 
(AH1263) were grown in TSB at 37°C, with aeration, a d treatments (vehicle versus 
Compound 1). The bacteria were stored at −20°C in RNAprotect c ll reagent, according 
to the manufacturer's recommendations (Qiagen), until the RNA was purified as 
previously described.193 Quantitative PCR (qPCR) were performed using an ABI 7900HT 
real-time PCR system with TaqMan Gene expression master mix, according to the 
manufacturer's directions (Applied Biosystems). Predesigned primer and probe sets 
(Integrated DNA Technologies, Coralville, IA) were used for the quantitation of RNAIII, 
psmα, and hla. The data are represented as the fold change relative to the concentration of 
16S rRNA. The primer and probe sets for the quantifica on of the S. aureus genes are 
listed in a previous publication.161 
 In silico docking on AgrAC. In silico docking calculations for each ligand (1 and 
ω-hydroxyemodin) was performed using the AutoDock 4.0 systems to predict the 
putative mode of binding on AgrAC. Compound 1 was prepared by assigning the 
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Gasteiger−Marsili atomic charges and nonpolar hydrogens on the crystal structure of the 
compound (XXX.cif) using AutoDockTools 1.5.4 (http://mgltools.scripps.edu/). 
Meanwhile, ω-hydroxyemodin was prepared for docking calculations in the same manner 
but applying a geometrically optimized structure for the compound. The optimized 
structure was built using Spartan’10  (www.wavefunction.com) with the optimization 
performed utilizing the software Gaussian 09 (Gaussi n Inc., Wallingford, CT, USA) at 
the DFT B3LYP/6-311+G(2d,p) level of theory. On theother hand, the AgrAC crystal 
structure (RSCB Protein Data Bank [www.pdb.org], PDB I  4G4K) was set by assigning 
all the non-polar hydrogens and Koleman charges to the receptor. A blind docking 
approach was performed to initiate the prediction, the best energy obtained from which 
was used as the initial conformation for subsequent simulations. Docking studies were 
done with Lamarckian Genetic Algorithm (LGA). The grid box for docking was set 
around a central atom of the ligand with dimensions f 40 × 40 × 40 Å. Parameters were 
set to an LGA calculation of 100 runs, whereas energy valuations were set to 2,500,000 
and 27,000 generations (repetitions of the process). The resulting docked poses were 
analyzed with AutoDockTools using cluster analysis, PyMOL.24. Molecular modeling 
images were prepared using PDB ID 3BS1 and PyMOL.  
   X-ray crystal diffraction analysis of compound 1. A specimen of C20H20O5, 
approximate dimensions 0.140 mm x 0.200 mm x 0.300 mm, was used for the X-ray 
crystallographic analysis. The X-ray intensity data were measured on a Bruker APEX 
CCD194 system equipped with a graphite monochromator and a MoKα sealed tube (λ = 
0.71073 Å). The frames were integrated with the Bruke  SAINT software195 package 
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using a narrow-frame algorithm. The integration of the data using a triclinic unit cell 
yielded a total of 17054 reflections to a maximum θ angle of 29.99° (0.71 Å resolution), 
of which 9966 were independent (average redundancy 1.711, completeness = 98.7%, Rint 
= 2.33%, Rsig = 4.66%) and 8084 (81.12%) were greater than 2σ (F2). The final cell 
constants of a = 7.3973 (5) Å, b = 11.0738 (8) Å, c = 12.0820 (9) Å, α = 69.8100 (10)°, β 
= 77.6290 (10)°, γ = 77.2120 (10)°, volume = 895.52 (11) Å3, are based upon the 
refinement of the XYZ-centroids of 4964 reflections above 20 σ(I). Data were corrected 
for scaling using the multi-scan method (SADABS)196. The calculated minimum and 
maximum transmission coefficients (based on crystal size) are 0.9730 and 0.9870. 
The structure was solved and refined using the Bruker SHELXTL Software 
Package, using the space group P 1, with Z = 2 for the formula unit, C20H20O5. The final 
anisotropic full-matrix least-squares refinement on F2 with 465 variables converged at 
R1 = 4.63%, for the observed data and wR2 = 12.30% for all data. The goodness-of-fit 
was 1.040. The final structural model was refined as an inversion twin with a BASF 
value of 0.4(8).  The largest peak in the final difference electron density synthesis was 
0.334 e-/Å3 and the largest hole was -0.207 e-/Å3 with an RMS deviation of 0.043 e-/Å3. 
On the basis of the final model, the calculated density was 1.262 g/cm3 and F(000), 360 
e-. Crystal data, data collection and structure refinement details are summarized in the 
supplementary material. The x-ray crystallographic data for 1 have been deposited with 
the Cambridge Crystallographic Data Center under accession number CCDC####. 
These data can be accessed free of charge at http://www.ccdc.cam.ac.uk/. 
134 
 
  Computational details. The TDDFT calculations, such as ECD and optical 
rotation, were performed according to a previous work utilizing Gaussian’09 program 
package.197  A 3D model of 1 was built and geometry optimized using Spartan’10 
software (www.wavefunction.com). Conformational analysis was performed by a Monte 
Carlo search protocol as implemented in the same software under semiempirical method 
(PM3). The resulting conformers were filtered, checked for duplicity, and minimized 
using a DFT force field at the B3LYP/6-311+G(2d,p) level of theory. ECD calculations 
using the self-consistent reaction field with conductor-like continuum solvent model in 
CH3CN were subsequently performed on the obtained DFT-minimized major conformers 
of both 9R and 9S enantiomers of compound 1. Following which, the excitation energy 
(nm), rotatory strength (R) in dipole velocity (Rvel) and dipole length (Rlen) forms 
obtained from the calculations were then used to simulate the ECD curves. 
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Figure 78. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 1 in CDCl3. 
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Figure 79. 1H-13C Edited-HSQC Spectrum of 1 in CDCl3.  
 
 
Figure 80. HMBC Spectrum of 1 in CDCl3. 
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Figure 81. NOESY Spectrum of 1 in CDCl3. 
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Figure 82. 1H NMR (400 MHz; Top) and 13C NMR (100 MHz; Bottom) Spectra of 2 in CDCl3.
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Figure 83. 1H-13C Edited-HSQC Spectrum of 2 in CDCl3. 
 
 
 
 Figure 84. HMBC Spectrum of 2 in CDCl3.
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Figure 85. 1H NMR (500 MHz; Top) and 13C NMR (125 MHz; Bottom) Spectra of 3 in CDCl3. 
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Figure 86. 1H-13C Edited-HSQC Spectrum of 3 in CDCl3. 
 
 
 
Figure 87. HMBC Spectrum of 3 in CDCl3. 
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Figure 88. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 4 in CDCl3. 
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Figure 89. 1H NMR (700 MHz; Top) and 13C NMR (175 MHz; Bottom) Spectra of 5 in CDCl3.
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Figure 90. Phylogram of the Most Likely Tree (-lnL = 14302.40) From a 
RAxML Analysis of 117 Taxa Based on Partial LSU Sequence Data (830 
bp). Numbers refer to RAxML bootstrap support values ≥ 65% based on 1000 
replicates. Thickened branches indicate Bayesian Probabilities ≥95%; strain 
G730 is identified as Leotiomycetes sp. (Bold, highlighted in blue.  A 30 d old 
culture on Potato Dextrose Agar media is shown on the left. Bar indicates 
nucleotide substitutions per site. 
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Figure 91. The Purity Evaluation of Compound 1 (99%) Data was obtained 
via a Waters Acquity UPLC system (Waters Corp., Milford, MA, USA) 
utilizing a Waters BEH C18 column (1.7 µm; 2.1 x 50 mm) and a CH3CN-H2O 
from 15% to 100% CH3CN over 4.0 min. The UV absorbance was monitored 
at 254 nm. 
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Table 30. Crystal Data for Compound 1. 
 C20H20O5 Z = 2 
Mr = 340.36 F(000) = 360 
Triclinic, P1 Dx = 1.262 Mg m-3 
a = 7.3973 (5) Å Mo Kα radiation, λ= 0.71073 Å 
b = 11.0738 (8) Å Cell parameters from 4964 reflections 
c = 12.0820 (9) Å θ = 3.6–29.9° 
α = 69.810 (1)° µ = 0.09 mm-1 
β = 77.629 (1)° T = 193 K 
γ = 77.212 (1)° Irregular, colourless 
V = 895.52 (11)  Å3 0.30 × 0.20 × 0.14 mm 
 
 
Table 31. Crystal Data Collection Parmeters for Compound 1. 
 
Data collection 
 Bruker APEX CCD  
diffractometer 
8084 reflections with I > 2σ(I) 
Radiation source: sealed tube Rint = 0.023 
Graphite monochromator θmax = 30.0°, θmin = 3.6° 
 ϕ and ω scans h = -1010 
17054 measured reflections k = -15->15 
9966 independent reflections l = -16->16 
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Table 32. Refinement Details for Compound 1. 
Refinement 
 Refinement on F2 Secondary atom site location: difference 
Fourier map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2σ(F2)] = 0.046 H-atom parameters constrained 
wR(F2) = 0.123  w = 1/[σ2(Fo2) + (0.0675P)2]   
where P = (Fo2 + 2Fc2)/3 
S = 1.04 (∆/σ)max < 0.001 
9966 reflections ∆>max = 0.33 e Å-3 
465 parameters ∆>min = -0.21 e Å-3 
3 restraints Absolute structure:  Refined as an inversion 
twin. 
Primary atom site location: structure-
invariant direct methods 
Absolute structure parameter: 0.4 (8) 
Special details 
 Geometry. All esds (except the esd in the dihedral angle betwe n two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by 
crystal symmetry.  An approximate (isotropic) treatment of cell esds is used for 
estimating esds involving l.s. planes. 
Refinement. Refined as a 2-component inversion twin. 
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CHAPTER V 
ENHANCED DEREPLICATION OF FUNGAL CULTURES VIA USE OF 
 
MASS DEFECT FILTERING 
 
 
This chapter has been published in The Journal of Antibiotics and is presented in 
that style. Noemi D. Paguigan, Tamam El-Elimat, Diana Kao, Huzefa A. Raja, 
Cedric J. Pearce, Nicholas H. Oberlies. The Journal of Antibiotics (2017) 
70, 553–561. 
 
 
Effective and rapid dereplication is a hallmark of present-day drug discovery from 
natural sources. This project strove to both decrease the time and expand the structural 
diversity associated with dereplication methodologies. A 5 min liquid chromatographic 
run time employing heated electrospray ionization (HESI) was evaluated to determine 
whether it could be used as a faster alternative over the 10 min ESI method we reported 
previously. Results revealed that the 5 min method was as sensitive as the 10 min method 
and, obviously, was twice as fast. To facilitate dereplication, the retention times, UV 
absorption maxima, full-scan HRMS and MS/MS were cross-referenced with an in-house 
database of over 300 fungal secondary metabolites. However, this strategy was dependent 
upon the makeup of the screening in-house database. Thus, mass defect filtering (MDF) 
was explored as an additional targeted screening strategy to permit identification of 
structurally related components. The use of a dereplication platform incorporating the 5 
min chromatographic method together with MDF facilitated rapid and effective
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 identification of known compounds and detection of structurally related analogs in 
extracts of fungal cultures. 
Introduction  
As Ōmura and colleagues showed the world via their research on avermectins198-
200 (and many other compounds), Nature is a prolific source of chemical diversity, 
providing humanity with many drugs and drug leads for a suite of diseases.2,3,201 A 
common characteristic of natural product extracts is that they consist of a mixture of 
compounds, often structurally related, although present at varying abundance. As such, it 
is desirable to have a means to prioritize samples, such that valuable time and financial 
resources can be focused on those extracts most likely to yield new structural diversity. 
An important part of this discovery process involves d replication, a rapid identification 
of known compounds in extracts in order to focus on the isolation of new chemical 
entities. Several recent advancements in dereplication strategies, most involving 
hyphenated spectroscopic techniques, have been pivotal to the increased efficiency in 
natural products-based drug discovery.202-204 In particular, mass spectrometry coupled 
with electrospray ionization (ESI) has become increasingly more important in natural 
products drug discovery, especially for chemical profiling of complex extracts.205-207 
Hyphenation of liquid chromatography with ESI-MS has increased the pace of 
dereplication by providing an efficient means of identifying the multiple components of 
complex extracts prior to further purification and isolation work.204,208  
Our research team has been working on the dereplication of fungal cultures for 
about a decade, particularly within a drug discovery program that aims to identify new 
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anticancer lead compounds.50,209 This started with a generalized dereplication 
methodology utilizing UV and 1H NMR spectra and targeting distinct classes of 
mycotoxins,210 as these nuisance compounds yield positive results in cytotoxicity-based 
assays. This protocol evolved significantly to target a wider range of secondary 
metabolites in fungal extracts using a complementary suite of hyphenated techniques, 
specifically ultraperformance liquid chromatography-photodiode array-high resolution 
tandem mass spectrometry (UPLC-PDA-HRMS-MS/MS). Finally, the latter was 
augmented with a droplet-liquid microjunction-surface sampling probe (droplet-LMJ-
SSP), so as to analyze the secondary metabolite profile of fungal cultures in situ.129 
Mass defect filtering was developed recently and is finding growing use in drug 
metabolite profiling studies.211-213  This approach utilizes the full scan-HRMS data, and
detection of drug metabolites is accomplished via dat  mining post acquisition. Mass 
defect filtering is based on the fact that each isotope of every element has a defined mass 
defect (i.e. the non-integral portion of an m/z value). This is why each molecule of a 
defined elemental composition will have a unique exact mass, typically observed in the 
1000ths to 10,000ths place. 
The useful application of mass defect filtering in drug metabolism studies is 
centered on the observation that the core structure of a drug does not change significantly 
during biotransformation.211,214,215 Thus, the mass defect between the parent drug and its 
metabolites will fall within a narrow range (typically within 50 mDa). If a mass defect 
filter window is centered on the mass defect of the parent drug, then ions with a mass 
defect outside of this window will be excluded, resulting in the removal of interference 
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signals in the total ion chromatogram (TIC). Importantly, this then facilitates the selective 
identification of drug metabolite peaks from the noise in complex biological matrices. 
Aside from drug metabolite identification, mass defect filtering has been adapted 
for use in the qualitative examination of natural products, particularly those based on 
herbals.216-218 However, this data-mining tool has not been used in the analysis of fungal 
secondary metabolites. Theoretically, compounds produced by fungi can be classified 
into distinct classes, each class sharing the same core structure. Thus, if a filter reference 
and substituents around the core structure are carefully defined, then mass defect filters 
can be constructed to exclude the majority of unrelated ions. This should, in turn, 
facilitate the identification of structural analogues in the extract. 
In this study, mass defect filtering is presented as an additional approach for the 
targeted screening of secondary metabolites in fungal extracts. The merger of UPLC-
PDA-HRMS-MS/MS dereplication with mass defect filtering permits additional profiling 
for structurally related components in the sample based on their mass defects (Figure 92). 
This workflow enhances the dereplication methods so as to screen for a wider range of 
secondary metabolites produced by fungal cultures.  
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Figure 92.  Proposed Workflow for Dereplication of Fungal Extracts Including a 5-
Minute UPLC-PDA-HRMS-MS/MS Methodology. HRMS and MS/MS (CID 30) data 
were acquired by LTQ Orbitrap using data dependent scan. A post-acquisition data 
analysis using IntelliXtract, an add-in feature of ACD MS Manager, cross-references the 
molecular-ion peaks and retention times to identify compounds known to the in-house 
database. For targeted-analysis of a specific classof compounds, a user-defined mass 
defect filtering criteria was designed based on accurate masses and mass defects centered 
around a core structure. The HRMS data were filtered with Compound DiscovererTM 
software to identify components related to the know compounds. The identity of the 
known compounds were verified based on HRMS, MS/MS fragmentation pattern, 
retention time, and UV absorption maxima. The tentative identity of the discovered 
unknown compounds were assigned based on the interpretation of their CID-MS/MS (30 
eV) fragmentation patterns. 
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Results and Discussion 
5-min HESI method. Previously, we developed a dereplication method for 
diverse classes of fungal secondary metabolites50 in extracts on an LTQ Orbitrap.219 That 
protocol utilized a 10-min liquid chromatographic run time to acquire full-scan HRMS 
and MS/MS (using a normalized collision energy of 30) spectra in both positive and 
negative electrospray ionization (ESI) modes, with UV absorption maxima and retention 
times used as orthogonal data. To facilitate dereplication, these data were uploaded into 
ACD MS Manager with add-in Intelliextract software, which cross-references the 
molecular-ion peaks and retention times with an in-house database of over 300 fungal 
secondary metabolites. Molecular ions identified by the software that matched the 
database were confirmed by comparison of the HRMS, /MS, retention time, and UV 
data to that of the standard in the database. With this method, nearly all of the fungal 
metabolites (>98 %) in the in-house database ionized efficiently in the ESI+ mode, while 
about 90% of the samples ionized in the ESI- mode. In total, this suggested the ESI+ 
mode as the ionization of choice for sample dereplication, unless knowledge of the 
samples or extracts indicated ionization in ESI- mode. 
While valuable for routine analysis of a large number of samples (batches of > 50 
samples), the 10-min liquid chromatographic method was not ideal, particularly for 
shared instruments. Thus, a dereplication method utilizing a 5-min run time at a 0.6 
mL/min flow rate via heated electrospray ionization (HESI) was evaluated to determine if 
it could be used as a faster alternative. The use of HESI was important,220,221 as it would 
 
154 
 
allow better desolvation, given that a higher flow rate (twice as fast) was used for the 5-
min method compared to the 0.3 mL/min flow rate utilized in the 10-min method. 
As proof of concept, about a third of the fungal library (>100 compounds) was 
analyzed in the HESI+ using the 5-min method to obtain the retention times, UV 
absorption maxima, full-scan HRMS and MS/MS spectra. In general, data obtained for 
all compounds matched with data in the database built using the 10-min dereplication 
method,219 except for the retention times.  
To compare the performance characteristics of the 10-min ESI dereplication 
method to the 5-min HESI dereplication, the two relat d parameters, limit of detection 
(LOD) and limit of quantitation (LOQ), were measured for each method, both in the 
positive ionization mode. The LOD and LOQ values were obtained from the calibration 
data and regression line directly (Supplementary Figures 99 and 100). Five representative 
compounds (1-5) were tested that had molecular weights ranging from 373 amu to 1963 
amu, and this included compounds that were based on polyketide building blocks, amino 
acid building blocks, and those with both in their scaffolds (Supplementary Table 33). In 
general, the 5-min HESI method had comparable sensitivity to the 10-min ESI method 
based on the LOD and LOQ values obtained for the five analytes tested (Supplementary 
Table 33).  
Dereplication of fungal extracts. An extract of MSX40080 was dereplicated and 
determined to contain aflatoxins, thus explaining its potent cytotoxicity.219 To test if the 
5-min method would be able to identify the same aflatoxins, the extract was re-analyzed 
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(Figure 93). Five aflatoxins, including sterigmatocystin (6), 5-methoxysterigmatocystin 
(7), aversin (8), brevianamide P (9), and 6, 8-di-O-methyl averufin (10) were identified, 
consistent with previous results.219 Comparison of data obtained from both methods 
indicated that only the retention times were different for the detected compounds, as 
shown for 6 (Figure 94) and 7-10 (Supplementary Figure 101). In the context of 
discovering leads for an anticancer drug discovery program, aflatoxins are an obvious 
nuisance, making their rapid dereplication critical. 
 
 
Figure 93. (A) (+)-ESI-TIC of MSX40080. (B) The Selcted Ion Chromatogram 
(SIC) of Dereplicated Aflatoxins (6-10) in MSX40080.
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Figure 94. Comparison of SIC (m/z 325), (+)-HRMS, CID MS/MS  (30 eV), and UPLC PDA Data of 
Sterigmatocystin (6) Detected in MSX40080 Using (A) the 5-Minute and (B) the 10-Minute Dereplication 
Protocols.
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Dereplication using UPLC-PDA-HRMS-MS/MS with mass defect filtering. 
The first step of the dereplication strategy was focused on the targeted screening of 
secondary metabolites in our library using the 5-min UPLC-HRMS-MS/MS 
methodology. To take this dereplication strategy a step further, identified hits were 
expanded upon by screening for potential analogues with the aid of Compound 
DiscovererTM data-processing software utilizing mass defect filtering (MDF). MDF was 
essential to remove the majority of interfering ions and facilitate detection of the potential 
structural class of related compounds via post-acquisition processing of HRMS data. 
Theoretically, each structural analogue possessed relatively minor and well-defined 
changes in the mass defect from filter reference compounds. Therefore the mass defects 
between the reference skeletons and related analogues should fall within a defined mass 
defect window. 
The case of identifying epipolythiodioxopiperazine (ETP) alkaloid analogues in 
different fungal cultures illustrates the use of the UPLC-PDA-HRMS-MS/MS 
dereplication strategy and the benefits of mass defect filtering. Recent studies have 
identified verticillin A (11) as an effective tumor suppressor, inducing tumor cell 
apoptosis in metastatic human colorectal cancer cells at nanomolar concentrations,222,223 
and structurally-related analogues have been shown t  have potent biological 
activities.224,225,226 Therefore it was valuable to identify these compounds in extracts, and 
at the same time, determine the presence of structurally-related analogues that were not 
part of our library. In this case we were using dereplication as a means to identify other 
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fungi that biosynthesize these compounds, with the aim of enhancing scale up and 
production, as will be reported in the future. 
  A common characteristic of the 15 analogues, all being dimeric ETPs, is a 
polysulfide bridge in the molecule (Dictionary of Natural Products, Taylor and Francis 
Group, UK). Supplementary Figure 102 is a graphical representation of the accurate 
masses and the corresponding mass defects of these compounds. As summarized in 
Supplementary Table 34, the compounds fall into a narrow range of nominal masses and 
mass defects.  To identify these analogues, a filtering template was set using the structure 
of Sch 52901 (12) having a nominal mass that is the midpoint of the target compounds, 
and setting a mass window of ± 150 Da. The analogues show a narrow range of mass 
shifts as a result of modifications in the structures, yielding only a small difference in 
mass defects relative to the template core structure 12 (Supplementary Table 34). Using a 
slightly wider mass defect range covering all the potential target compounds 
(Supplementary Table 34), a mass defect window of ± 50 mDa was used.  
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The applicability of mass defect filtering for detecting these analogues was 
illustrated with the analysis of an extract obtained from a culture of Clonostachys 
rogersoniana (MSX59553), which was previously identified by our research group as a 
 
 
Figure 95. The (+)-ESI-TIC of MSX59553 and Epipolythiodioxopiperazine 
 Analogues (11-16) Dereplicated via the 5-Min UPLC-PDA-HRMS-MS/MS   
(CID 30 eV) Method. 
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Bionectriaceae sp. (Hypocreales) based on partial 28S rDNA sequence data, JQ749725 
and known to biosynthesize ETP alkaloids.226 Dereplication of this strain using the 5-min 
HESI+ method identified six known ETPs, including verticillin A ( 11), Sch 52901 (12), 
verticillin H (13), 11´-deoxyverticillin (14), Sch 52900 (15), and gliocladicillin C (16) 
based on retention times, HRMS, and MS/MS data (Figure 95 and Supplementary Figure 
103). The TIC of MSX59553 was analyzed further by mass defect filtering with the aim 
of revealing additional structurally-related analogues. Mass defect filtering significantly 
reduced the amount of interfering ions (Supplementary Figure 104), facilitating 
identification of related analogues that were present in the extract. The characteristic 
peaks of ETPs captured by mass defect filtering was con istent with the verticillins 
identified in the previous analysis.  
Identification of the fragmentation pattern for ETP alkaloids. The benefit of 
using mass defect filtering in conjunction with theraditional targeted dereplication 
strategy is that it gives additional insight into the remaining unknown compounds present 
in the extract by simplifying the data. Once a potential structurally-related compound 
based on mass defect is identified, its structure must be confirmed. But, with the absence 
of a standard, this might be a challenging task. Thus, to facilitate characterization within 
the context of an extract, the characteristic CID fragmentation can be analyzed to 
tentatively assign a structure. In the literature, several studies have been reported that use 
a CID-MS/MS-based workflow for structural elucidation of natural products.227-229 
Implementation of this strategy requires knowledge of the fragmentation patterns of 
compounds in the same structural class. 
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Compounds having the same core substructure generally xhibit similar mass 
fragmentation patterns, and thus, can be identified based on their diagnostic fragment 
ions.218 For the case of ETP alkaloids, the recurrent fragmentation pattern was 
characterized based on the MS/MS CID fragmentation taken in positive mode 
(Supplementary Figure 103). In general, desulfurization of the precursor ion peak ([M-
2S+H]+, arising from the polysulfide bridge in each of the dioxopiperazine rings, were 
observed in all CID-MS/MS analyses. Nearly all compunds exhibited dehydration of the 
[M-2S+H]+ ion, whereas the compound 11´-deoxyverticillin A (14), which possessed one 
hydroxy group, did not. This may indicate that the removal of a H2O was dependent on 
the number of hydroxy moieties in the compounds. After H2O loss, a fragment peak, 
indicating loss of one of the dioxopiperazine moieties was observed. For instance in 
verticillin A, the fragment peak at m/z 615.18 was followed by a peak at m/z 465.08, 
corresponding to a difference of 150 Da and accounting for the loss of a dioxopiperazine 
moiety (C7H6N2O2). After this observed dissociation, dehydration and desulfurization 
occurred, most likely in the other dioxopiperazine moiety of the core. 
With the examination of the CID diagnostic fragment ions of the ETP standards 
(Supplementary Figure 103), we sought to apply this to the rapid characterization of 
analogues of the ETPs in other complex mixtures, where no available laboratory standard 
was available.
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Figure 96. Detection of Verticillin D (17) in G35 Grown in Oatmeal Agar After Mass 
Defect Filtering. (A) Overlay of (+)-ESI TIC of 17. (B) CID MS/MS (30 eV) Spectra 
of 17. 
 
 
Analysis of verticillin production in G35.  A culture of Colletotrichum fioriniae 
(G35) was identified previously by dereplication to pr duce 11 and 15.230 However, 
refermentation of the culture using the standard rice culture conditions failed to produce 
any structurally-related analogues. In order to revive the ETP biosynthetic pathway, the 
one strain-many compounds (OSMAC) approach was applied.231 Using this strategy, 12 
different growth conditions providing different nutrients were tested to identify the most 
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favorable condition that would lead to the revival of the biosynthetic pathway. Still, no 
analogues were dereplicated in any of the extracts.  
Upon analysis of the HRMS data with mass defect filtering, a culture of G35 
grown in oatmeal agar showed a peak that had a corresponding value at m/z 757.1212, 
which matched the monoisotopic mass of protonated verticillin D (17) with +3.3 ppm 
mass accuracy (Figure 96). The peak with m/z 757.1212 was identified as an ETP 
alkaloid based on comparison of the characteristic losses observed in its MS/MS 
spectrum (Figure 96), exhibiting a distinctive fragmentation pattern similar to that of 
verticillin A (Supplementary Figure 103). In particular the fragment ions at m/z 693.11 
and m/z 675.10 indicated desulfurization and dehydration, respectively.   
Coincidentally, 17 was isolated from a freshwater Ascomycete fungal culture of a 
Clonostachys sp. (G600), and this presented an opportunity to verify the identity of the 
peak observed in G35.  The HRMS and MS/MS data for 17 were analyzed and matched 
that of the compound with m/z 757.1212 from G35 (Figure 96). This result verified that 
17 was indeed being produced in low quantities by G35in oatmeal agar, an observation 
that would not be possible without mass defect filtering.  
This result demonstrated the advantages of incorporating mass defect filtering as a 
processing technique in the dereplication platform. Verticillin D (17) was not part of the 
database when the samples were dereplicated and processed originally. Since mass defect 
filtering is a post-acquisition data mining technique that analyzes solely the HRMS data, 
samples can be re-evaluated as more data become available.  
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Figure 97. Analysis of the Extract of G600 and G416 Grown Alone and In Co-
culture Using Dereplication with Mass Defect Filtering to Determine the Production 
of Induced Secondary Metabolites. (A) Overlay of (+)-ESI TIC of the samples. (B) 
Overlay of (+)-ESI TIC of the samples after mass defect filtering. 
 
 
Co-culture analysis using dereplication with mass defect filtering. Analysis of 
the extract of G600 and a strain of Lindgomyces madisonensis (G416) grown in co-
culture illustrates the use of dereplication with mass defect filtering to determine the 
production of induced secondary metabolites. In this case, the goal was to determine the 
presence of structurally-related ETPs in the extract. As mentioned previously, G600 was 
determined to biosynthesize 17; G416, on the other hand, was known to produce mainly 
polyketides.171  The co-culture was analyzed, and the resulting mass defect profile was 
compared with separate cultures of G600 and G416 (Figure 97). As expected, 17 was 
identified and appeared to be the most abundant in both G600 and in the co-culture 
(Supplementary Figure 105). Further inspection of the mass defect profile of the cultures 
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indicated that the co-culture had a peak at m/z 755.1062 that was not detected in a 
monoculture of G600. The accurate mass for the detected molecular ion peak matched 
that of verticillin F (18), a dimeric ETP alkaloid, at -3.0 ppm mass accuracy (Figure 98). 
The MS/MS fragmentation for the peak indicated desulfurization of the precursor ion 
peak (m/z 690.16), followed by dehydration (m/z 673.03), possible loss of one of the 
dioxopiperazine moieties (m/z 495.01), and then desulfurization and dehydration (m/z 
413.22), all consistent with the distinctive dissociation of ETPs (Figure 98). Based on this 
observation, the molecular ion peak identified could be tentatively assigned as verticillin 
F (18) with the absence of a standard for confirmation. 
Interestingly, the mass defect profile for a monoculture of G416 exhibited a peak 
at m/z 683.1545. However, the MS/MS profile for that peak did not display the 
characteristic pattern indicative of an ETP alkaloid (Supplementary Figure 106). This 
suggested that the detected peak was a false positive and illustrates how MS/MS data can 
be used to either verify or refute potential hits. 
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Figure 98. Verticillin F Detected by Mass Defect Filtering in Co-Culture G416 and 
G600. (A) (+)-ESI SIC of m/z 755.1058 within a ± 5 ppm accuracy. (B) (+)-HRMS of 
peak at 3.06 min with predicted elemental compositin matching the protonated mass of 
verticillin F with -3.0 ppm accuracy. (C) CID MS/MS (30 eV) spectrum of m/z 755 
showing the distinct fragmentation pattern of an ETP alkaloid and consistent with the 
structure of 18. 
 
 
Conclusion 
A method to dereplicate fungal extracts was further optimized. This methodology 
improves a previous dereplication strategy by combining two schemes: a) Targeted 
screening of compounds known to an in-house built database using a 5-min UPLC-PDA-
HRMS-MS/MS where a heated electrospray ionization source (HESI) was utilized and 
ACD/IntelliXtract software to facilitate the dereplication; b) Mass defect filtering of 
resulting accurate mass full-scan raw data for a tage ed identification of selected known 
natural products.  In particular, mass defect filtering is a data mining technique that can 
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be applied post acquisition, permitting the re-evaluation of data when future compounds 
of interest are identified. 
Experimental Section 
Fungal samples. All fungal samples used in this study were from eith r the 
Mycosynthetix (MSX) culture collection (Hillsborough, NC, USA) or the University of 
North Carolina at Greensboro, Department of Chemistry and Biochemistry, Fungal 
Culture Collection.  
Isolation and identification of fungal strains. Dr Barry Katz isolated 
Mycosynthetix fungal strain MSX59553 in January of 1992 from leaf litter,226 while 
strain MSX40080 was isolated from oak leaf litter on September of 1988.  Strain G600 
was isolated from submerged wood from fresh water in Knight-Brown Nature Preserve in 
North Carolina, USA (N 36 18.861', W 80 0.423'). Strain G35 was isolated and identified 
from surface sterilized seeds of Hydrastis canadensis (goldenseal) as Colletotrichum 
fioriniae (KX110401).230 In addition to examining the micro-morphological 
characteristics, for molecular identification of new strains dereplicated in the present 
study (MSX59553 and G600), the internal transcribed spacers (ITS) region of the nuclear 
RNA operon was sequenced and analyzed via BLAST search. In addition, we constructed 
a Maximum Likelihood (ML) phylogenetic tree by incorp rating ITS sequences from the 
newly sequenced strains along with ITS sequences used in a recent study on molecular 
identification of Clonostachys spp232 based on the outcome of results from BLAST 
search. Methods for sequencing of the strains, BLAST search, and ML phylogenetic 
analysis have been summarized previously.122,233-235 Based on morphological and 
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molecular data, MSX59553 is identified as Clonostachys rogersoniana,236 since it 
occurred in a strongly supported clade (99% PHYML bootstrap support) with other 
sequences of C. rogersoniana including a reference strain CBS 582.89, while G600 is 
identified as Clonostachys sp. Maximum Likelihood tree along with micro morphological 
characters of the newly sequenced strains are presented in the Supplementary Figure 107 
and 108. The newly obtained sequences from this study have been deposited in GenBank 
(accession no.  KX845687, KX845688). 
Fermentation and extraction of fungal cultures. Fungal cultures were grown as 
described previously.99,226 Once the screener cultures were generated, 60 mL of 1:1 
CH3OH-CHCl3 was added into each flask, followed by shaking for ∼16 h at rt on an 
orbital shaker set at ∼100 rpm. The resulting mixtures were filtered under vacuum. To 
the filtrate 90 mL of CHCl3 and 150 mL of H2O were added, and the mixture was stirred 
for 30 min and then transferred into a separatory funnel. The bottom layers were drawn 
off and dried in vacuo. The dried organic extracts were defatted by reconstituting in a 
mixture of 100 mL of 1:1 CH3OH-CH3CN and 100 mL of hexane, and then partitioned. 
The CH3OH-CH3CN layers were collected and concentrated in vacuo.  
For G35, from the seed culture, an inoculum was transferred onto five 100 mm x 
15 mm Petri dishes with solid oatmeal agar mix. Thecultures were then allowed to grow 
for 28 days at rt before they were extracted. Extraction of these samples were performed 
in the same way as the screener cultures.  
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UPLC-PDA-HRMS-MS/MS. Fungal extracts were dissolved with CH3OH-
dioxane (1:1, v/v) to obtain a final concentration of 2 mg/mL. UPLC-HESI-HRMS-
MS/MS was performed on an Acquity UPLC system (Waters, Massachussets, USA) 
equipped with a cooled autosampler kept at 10 °C, photodiode array detector (PDA), 
column manager, and binary solvent manager; all coupled to an LTQ-Orbitrap XL mass 
spectrometry system (Thermo Finnigan, San Jose, CA, US ) with a heated electrospray 
ionization source (HESI).  
UPLC separations were performed at 40 °C on a 50 mm x 2.1 mm i.d., 1.7 µm, 
Acquity BEH C18 column (Waters, Massachusetts, USA) equipped with a security guard 
pre-column. A linear CH3CN-H2O gradient of 15% CH3CN-H2O to 100% CH3CN in 4 
min was applied at a constant flow rate of 0.6 mL/min; then 100% CH3CN was 
maintained for 0.75 min before returning to the starting conditions in 0.25 min. All 
solvents used were acidified with 0.1% formic acid. PDA data were collected from 191 to 
499 nm with resolution of 3.6 nm at a 5 point per second sampling rate. 
The HESI source was operated in the positive ionization mode with the following 
conditions: vaporizer temperature set at 300 °C; capillary temperature set at 275 °C; 4.0 
kV for the source voltage; 9.0 V for the capillary voltage; and 100.0 V for the tube lens; 
Nitrogen sheath gas flow rate set at 35.00 arb. Full-scan HRMS data were acquired from 
m/z 100 to 2000. A collision-induced (CID) energy of 30 eV in the ion trap was used to 
obtain MS/MS fragmentation data. The system was controlled with Thermo Xcalibur 
software ver. 2.2.  
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The LC-MS raw data were processed by the add-in IntelliX ract feature of the 
ACD MS Manager (Advanced Chemistry Developments, Inc., Toronto, Canada). Mass 
defect filtering of the HRMS data was performed with Thermo Scientific Compound 
Discoverer software ver. 1.0. (Thermo Scientific, Inc, San Jose, CA). 
Limit of detection and limit of quantitation data analysis. Calibration curves 
were obtained by preparing two-fold serial dilutions of the standards, which were 
analyzed in triplicate via 3 µL injections. All LC-HRMS data were processed using 
Thermo Xcalibur to automatically integrate and calculate the MS signal peak area of each 
analyte over noise (S/N). Linearity of the calibration curve was assessed by least-squares 
analysis. The concentration of the analyte that gives the LOD (CLOD) and the 
concentration at LOQ (CLOQ) were calculated as 3 times the standard error of the 
regression line (sy/x) divided by the slope (b), and 10 times sy/x divided by b, respectively. 
The standards, alamethicin F50 (1), trichokonin VI (2), equisetin (3), acremonidin A (4), 
and acuminatum B (5) were dissolved separately in a 1:1 CH3 N-dioxane mixture to 
produce a 15726 µM stock solution of each. An aliquot from each standard solution was 
taken to prepare a 2621 µM multi-standard stock solution. A two-fold serial dilution of 
the multi-standard stock solution was prepared to make 20 standard solutions at 
concentrations ranging from 0.0025 µM to 1310 µM.  
  
 
171 
 
Supplementary Material 
 
 
 
Table 33. Comparison of Performance Characteristics of the 10-Min and 5-Min 
Dereplication Methods 
 
 
 
Analyte Structure and Molecular Weight 
(g/mol) 
10-min ESI 
method 
5-min HESI 
method 
LODa 
(µM) 
LOQb 
(µM) 
LODa 
(µM) 
LOQb
(µM) 
 
Alamethicin F50 (1)  
(1963.35) 
0.04 0.1 0.07 0.2 
 
Trichokonin VI (2) 
(1937.32) 
0.06 0.2 0.09 0.3 
 
Acuminatum B (3) 
(888.12) 
0.07 0.2 0.07 0.2 
 
Acremonidin A (4) 
(614.56) 
0.2 0.4 0.1 0.4 
 
Equisetin (5) 
(373.49) 
0.4 1 0.8 3 
aLOD, limit of detection as calculated by three times the standard error of the regression line 
divided by the slope (CLOD = 3sy/x ÷ b). bLOQ, limit of quantitation as calculated by ten times 
the standard error of the regression line divided by the slope (CLOQ = 10sy/x ÷ b). 
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Table 34. Nominal Mass and Corresponding Mass Defects for a Series of 
Epipolythiodioxopiperazine Alkaloid Analogues. 
 
Compound 
Nominal 
Mass (Da) 
Mass Defect 
(mDa) 
∆MDa 
(mDa) 
Verticillin A 696 95.3 -15.7 
11'-Deoxyverticillin A 680 100.4 -10.6 
11, 11'-Dideoxyverticillin A 664 105.5 -5.5 
Verticillin B 712 90.2 -20.7 
Verticillin C 744 67.4 -48.7 
Verticillin D 756 116.0 5.5 
Verticillin F 754 62.3 -10.2 
Verticillin E 752 116.4 -25.8 
Verticillin G 712 100.8 -20.7 
Verticillin H 724 85.1 15.7 
Sch 52900 726 90.2 -5.1 
Sch 52901 710 105.9 0.0 
Gliocladicillin A 694 111.0 5.1 
Gliocladicillin B 678 116.1 10.1 
Gliocladicillin C 740 121.1 10.6 
a ∆MD = (Mass defect of a compound – Mass defect of template structure) 
 
 
 
1
7
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 99. Calibration Curves for (A) Alamethicin F50 (1), (B) Trichokonin VI (2), (C) Acuminatum B (3), (D) Acremonidin 
A (4), and (E) Equisetin (5) Generated Using the 5-Min HESI Method. 
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Figure 100. Calibration Curves for (A) Alamethicin F50 (1), (B) Trichokonin VI (2), (C) Acuminatum B (3), (D) Acremonidin 
A (4), and (E) Equisetin (5) Generated Using the 10-Min ESI Method . 
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Figure 101. Dereplication Analysis of MSX40080. (A) Overlay of the (+)-ESI-TIC 
and SIC (m/z 325, 355, 369, 378, 397) of MSX40080 analyzed using the 5-min UPLC-
PDA-HRMS-MS/MS method. (B) Overlay of the (+)-ESI-TIC and SIC (m/z 325, 355, 
369, 378, 397) of MSX40080 analyzed using the 10-min UPLC-PDA-HRMS-MS/MS 
method. Dereplication analysis identified the aflatoxins as sterigmatocystin (6), 5-
methoxysterigmatocystin (7), aversin (8), brevianamide P (9), and 6, 8-di-O-methyl 
averufin (10) in MSX40080. 
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Figure 102. Parameters Used in Mass Defect Filtering Analysis to Detect  
Epipolythiodioxopiperazine Alkaloid Analogues. Based on the structures of 
a series of epipolythiodioxopiperazine alkaloid analogues (Table S2) a mass 
defect filtering reference was defined according to the structure of 12 
(C31H30N6O6S4). The mass defect filter window was then set at a mass 
tolerance of C31H30N6O6S4 ± 150 Da at ± 50 mDa mass defect. 
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Figure 103. The CID MS/MS (30 eV) Spectra of Compounds 11-16 (Displayed in 
Panels A-F, Respectively) Showing the Similarity of Their Characteristic Neutral 
Losses. 
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Figure 105. (A) Overlay of Chromatographic Peaks of Verticillin D (17). (B) CID 
MS/MS (30 eV) Spectra of 17. 
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Figure 104. Overlay of (A) (+)-ESI TIC of MSX59553 and (B) (+)-ESI TIC of 
MSX59553 After Mass Defect Filtering. 
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Figure 106. (A) (+)-ESI TIC of G416 After Mass Defect Filtering. (B) CID MS/MS  
(30 eV) of m/z 683.15. 
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Figure 107. Phylogram of the Most Likely Tree (-lnL = 1507.85) from a PHYML 
Analysis of 51 Isolates Based on Partial ITS rDNA (520 bp). Numbers refer to 
PHYML bootstrap support values ≥ 50% based on 1000 replicates. Newly sequenced 
strains MSX59553 and G600 are highlighted in colored boxes. A 3-week old culture of 
MSX59553 and G600 on Potato Dextrose Agar (Difco) is shown on the right. Bar 
indicates nucleotide substitutions per site. 
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Figure 108. Micromorphological Features of MSX59553 and G600 Cultures. (A) 3-
week culture of Clonostachys rogersoniana (MSX59553) on Potato Dextrose Agar 
(Difco) and micromorphological features such as conidi phores showing phialides and 
conidia; Scale bars = 20 µm. (B). A 3-week culture of Clonostachys sp. (G600) on Potato 
Dextrose Agar (Difco) showing conidia; Scale bars = 20 µm. 
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CHAPTER VI 
CONCLUSIONS 
 
 
The studies presented here have demonstrated the value of filamentous 
ascomycetes as an incredibly rich source of structual diversity for drug discovery. 
Different approaches to optimize the process of drug iscovery were used and these 
included use of structure-activity relationship studies starting with a known bioactive 
pharmacophore; exploration of understudied ecological groups for new chemistry; and 
development of dereplication strategies.  
In Chapter II we investigated the effect of fluorine substitution as a strategy to 
expand the medicinally relevant chemical space of isolated fungal metabolites starting 
with a known bioactive pharmacophore. Griseofulvin and five analogues (with one being 
new to literature) were isolated from Xylaria cubensis, and a series of fluorinated 
analogues were chemoselectively synthesized using Selectfluor. Principal component 
analysis (PCA) captured the variation in the molecular and physicochemical properties 
brought about by incorporation of a fluorine atom to the fungal secondary metabolites; 
and demonstrated that the fluorinated analogues occupied a different region of space than 
the isolated fungal metabolites. In Chapters III and IV, as part of our ongoing studies to 
explore the chemical mycology of freshwater ascomycetes from North Carolina, we 
investigated the chemical mycology of Lindgomyces madisonensis (strain G416) and 
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Leotiomycetes sp. (accessioned as G730). From L. madisonensis, collected from Big 
Beaver Island creek in Madison, North Carolina, seven acetophenone derivatives (five 
new to literature and two newly reported as natural p oducts) were isolated and 
characterized (Chapter III). In Chapter IV, chemical nvestigation of Leotiomycetes sp., 
collected from a freshwater lake in Hanging Rock State Park, North Carolina, led to the 
isolation and identification of three new prenylated xanthenes and two known 
compounds. Biological evaluation of the new prenylated xanthenes indicated potential 
anti-virulence activity against a clinically relevant strain of methicillin resistant 
staphylococcus aureus. Overall, the studies presentd i  Chapters III and IV highlighted 
the importance of freshwater ascomycetes as source f n w chemistry and new drug 
leads. Lastly, in Chapter V, a method using a comple entary suite of hyphenated 
techniques, specifically ultra-performance liquid chromatography-photodiode array-high 
resolution tandem mass spectrometry to dereplicate fungal extracts was further 
optimized. This methodology improved a previous dereplication strategy by combining 
two schemes including targeted screening of compounds k own to an in-house built 
library followed by mass defect filtering that allowed screening for potential analogues.
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